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Introduction : Oesophageal cancer represents a formidable challenge to both patients 
and clinicians. Due to its propensity for early systemic dissemination, the majority of 
patients are not eligible for curative treatment. In the minority of patients suitable for 
surgical resection, there remain many controversies in management. Good prospective 
data from high volume centres is vital in attempting to improve staging algorithms and 
management strategies. 
 
Methods : A large prospectively collected database was utilised, the result of a 
research collaboration between two high volume oesophageal cancer centres (St 
Thomas’ hospital and Royal Marsden hospital) in London, UK. The database consisted 
of consecutive patients undergoing surgery for oesophageal or oesophago-gastric 
junction (type 1 and 2) tumours between 2000 and 2010. The database was rigorously 
cross-referenced to ensure accuracy. Data were analysed independently at an aligned 
academic unit by an experienced bio-statistician. The aim was to assess factors 
predicting early recurrence and death after oesophagectomy (study 1), the influence of 
surgical radicality on outcomes (study 2), and the down-staging effects of neo-adjuvant 
chemotherapy (study 3). Each of these was to be presented as a scientific article, 
accepted for peer-review publication. 
 
Results : Of the 680 patients included, the median age was 64 years with a male 
preponderance (81%). The majority of patients had adenocarcinoma (82%), although 
patients with squamous cell carcinoma (14%) and high grade dysplasia (4%) were also 
included in the database. Multivariable analysis showed T and N stage (T3-4 N2-3 OR 
10.6; 95% CI 2.8-40.0), poor differentiation (OR 2.8; 95% CI 1.4-5.5), involved 
resection margins (OR 2.7; 95% CI 1.2-6.0) and poor response to pre-operative 
chemotherapy (OR 3.2; 95% CI 1.1-8.8) to independently predict early recurrence and 
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death after surgery. The predominant mode of recurrence was with distant metastases. 
Surgical approach, comparing transhiatal with transthoracic oesophagectomy, had no 
impact on overall survival (HR 1.07, 95% CI 0.84 – 1.36) or tumour recurrence (HR 
0.99, 95% CI 0.76 – 1.29) when adjusted for potential confounding factors. In patients 
undergoing neo-adjuvant chemotherapy, outcome was determined by tumour stage 
after chemotherapy rather than that of initial presentation. This may have a significant 
impact on staging algorithms with a shift in focus to assessment of tumour stage after 
chemotherapy in order to improve clinical decision making and predict outcome. The 
three studies were published in the Journal of Surgical Oncology, British Journal of 
Surgery and Journal of Clinical Oncology respectively. 
 
Conclusions : Predictive models that could guide individualised patient management 
are achievable. These could include selecting patients for specific neo-adjuvant 
treatment strategies, guiding surgical approach in patients deemed suitable for 
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1.1 Oesophageal cancer 
 
1.1.1 Background on oesophageal cancer 
Oesophageal cancer represents a formidable challenge to both patients and clinicians. 
It is the eighth most common cancer worldwide and the sixth most common cause of 
cancer death in the UK [1]. Each year over 8,000 patients are diagnosed with 
oesophageal cancer in the UK which has a particularly high incidence of 
adenocarcinoma of the oesophagus [2]. It is a cancer with a propensity for early 
systemic dissemination aligned with a late onset of symptoms that often leads to 
delayed diagnosis. As a result, the majority of patients will not be eligible for curative 
treatment. The overall survival of patients diagnosed with oesophageal cancer in the 
UK between 2005 and 2009 was 13% at 5 years [2]. Even in those patients with 
resectable tumours, historical series have rarely shown five year survival to exceed 





1.1.2 Improvement in outcomes and centralisation of services 
Some cause for optimism lies in the recent advances in the staging and management 
of these tumours, including the widespread adoption of peri-operative oncological 
therapies. A number of cohort studies from specialist centres have shown improved 
five year survival with such strategies, reaching 50% in some published studies 
following surgery [5, 6]. Centralisation of services in the UK, and elsewhere, has been 
shown to improve survival [7-9] and reduce post-operative mortality [10, 11]. This has 
almost certainly contributed to the significant reduction in UK National audit mortality 
rates between 2000 and 2013, decreasing from 10% to 3% [12]. The concentration of 
resources into high volume centres has led to the development of specialist multi-
disciplinary teams (MDT) with a pooled expertise in radiology, oncology, anaesthesia, 
critical care and surgery amongst others. This MDT approach has also been shown to 




1.1.3 Classification and aetiology of Oesophageal cancer 
There is a significant geographical variation in the histological sub-type of oesophageal 
cancer. In the western world, the incidence of adenocarcinoma (AC) of the lower 
oesophagus and oesophago-gastric junction (OGJ) is increasing and has overtaken 
that of squamous cell carcinoma (SCC) [14, 15]. In south-east Asia, SCC remains the 
most prevalent and AC is rare. Risk factors for the development of SCC are tobacco 
smoking, alcohol excess, achalasia and genetic mutations amongst others [16, 17]. 
Barrett’s oesophagus, a pre-malignant condition caused by gastro-oesophageal reflux 
disease (GORD) is strongly associated with the development of adenocarcinoma [18-20]. 
Although arguably part of the same causal pathway, reflux, obesity, male sex, hiatus 
hernia and smoking are also associated with the development of adenocarcinoma.  
 
Tumours of the oesophago-gastric junction (OGJ) may be categorised according to 
their location relative to the true junction. The classification originally described by 
Siewert is most commonly used [21]. For the purposes of this thesis, oesophageal 
cancer refers to tumours of the oesophagus and OGJ (Siewert types 1 and 2). This 
grouping has been accepted as part of TNM 7, although there is particular controversy 
regarding type 2 tumours and whether they should be considered as oesophageal 
cancers, gastric cancers or a separate entity in their own right. 
 
Whilst AC and SCC sub-types share a common anatomical location i.e. the 
oesophagus, there is convincing evidence that they should be considered as distinct 
pathological entities by virtue of their differing aetiology, natural history and sensitivity 




Squamous carcinoma affects the native oesophageal squamous mucosa and by 
definition includes tumours of the proximal, mid and distal oesophagus. 
Adenocarcinomas, tend to arise from the glandular mucosa of the true OGJ or from a 
segment of Barrett’s oesophagus. As such these tumours are almost exclusively found 
in the lower oesophagus and OGJ. The pattern of dissemination may also be different 
with adenocarcinomas having a higher propensity for metastatic spread compared to 
squamous carcinomas which more frequently affect the mediastinal and cervical lymph 
nodes [23-27]. Finally, SCC is more sensitive to the effects of radiotherapy, hence the 
widespread use of definitive CRT in the treatment of proximal and mid oesophageal 
SCCs in the UK [28, 29]. The treatment of lower oesophageal SCC is more contentious 




1.1.4 Known Prognostic factors in oesophageal cancer 
Tumour stage – The most significant prognostic marker in oesophageal cancer is 
tumour stage, with more advanced tumours carrying a worse prognosis. The TNM 
staging classification is widely accepted, currently in its 7th edition. The AJCC 
classification further categorises tumours into stage-matched groups (I-IV) according to 
prognosis [30].  
 
A larger tumour, reflected by higher T stage, has a greater risk of lymph node 
metastases and in turn a higher probability of distant metastatic disease [31-34]. This 
stepwise progression of disease from primary tumour to lymph node metastasis to 
systemic disease has been widely acknowledged, however it is not a pre-requisite. 
Some patients are found to have systemic disease in the absence of lymphadenopathy 
and a further group may experience “skip” lymph node metastases. Local infiltration 
into structures such as the aorta or bronchi (T4 disease) can render a tumour 
unresectable. The natural history of inoperable oesophageal cancer from diagnosis to 
death is seldom greater than 12 months. 
 
In compiling the 7th edition TNM staging system, N status was re-classified according to 
the number of lymph node metastases (N0 – no lymph nodes involved, N1 : 1-2 LNs, 
N2 : 3-6 LNs, N3 >6 LNs). A number of studies have demonstrated that above a certain 
number of positive lymph nodes (range 3-8 lymph nodes) the likelihood of underlying 
systemic disease approaches 100%, and hence these patients are rarely cured by 
surgery [32]. Other studies have examined the ratio of involved LNs to total number 
resected, concluding that this ratio is a significant marker of prognosis [35]. Regardless 
of the method by which it is defined, nodal status is arguably the most influential 
prognostic factor in patients undergoing surgery for oesophageal cancer. 
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The presence of metastatic disease (haematogenous or peritoneal metastases and 
distant lymph node metastases) precludes a radical treatment pathway. Although other 
GI cancers, most notably colorectal carcinomas, are now considered for surgery in the 
presence of such metastases, particularly in the liver, the very poor prognosis of 
oesophageal cancer and the magnitude of the surgery, make this option 
unappealing [36]. However, some case series have reported reasonable survival in 




Fig. 1 Seventh edition TNM classifications. T is classified as Tis: high-grade dysplasia; T1: 
cancer invades lamina propria, muscularis mucosae, or submucosa; T2: cancer invades into but 
not beyond the muscularis propria; T3: cancer invades the para-oesophageal tissue, but does 
not invade adjacent structures; T4a: resectable cancer invades adjacent structures,such as 
pleura, pericardium, or diaphragm; and T4b: unresectable cancer invades other adjacent 
structures, such as aorta, vertebral body, or trachea. N is classified as N0: no regional lymph 
node metastasis; N1: regional lymph node metastases involving 1 to 2 nodes; N2: regional 
lymph node metastases involving 3 to 6 nodes; and N3: regional lymph node metastases 
involving 7 or more nodes. M is classified as M0: no distant metastasis; and M1: distant 
metastasis [38]. (Reprinted with permission, Cleveland Clinic Centre for Medical Art & 




Fig. 2 Stage groupings for M0 adenocarcinoma by T and N classification and histologic grade 
(G) [38]. (Reprinted with permission Cleveland Clinic Centre for Medical Art & Photography 
2001–2012. All Rights Reserved) 
 
Tumour grade - The measure of tumour differentiation (well, moderately, poorly or un-
differentiated) has been shown in numerous studies to affect prognosis [34]. Poorly 
differentiated tumours are more unstable, increasing the likelihood of metastases. 
Additionally, the cell populations within a poorly differentiated tumour may be more 
heterogeneous, making them less likely to respond to generic systemic therapies.  
 
Lymphovascular invasion - The ability of a tumour to invade blood vessels, 
lymphatics and nerves determines its ability to metastasise. It is not surprising, 
therefore, that lympho-vascular invasion at a microscopic level is associated with poor 
prognosis. 
 
Completeness of resection (R0/1/2) -  Incomplete surgical resection, with 
microscopic (R1) or macroscopic (R2) margin involvement is associated with poor 
prognosis [39]. In oesophageal cancer, the circumferential margin (CRM) is particularly 
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vulnerable due to the absence of a serosal layer in the oesophagus, and the minimal 
volume of peri-oesophageal fat to separate the tumour from adjacent structures. 
Longitudinal margin involvement is rare, and seldom the cause of death, as these 
patients generally die of metastatic disease [40]. Although CRM involvement is directly 
related to tumour T stage (and by association, therefore, a higher risk of lymph node 
involvement), an R1 resection has been shown to be an adverse prognostic marker in 
numerous studies that have adjusted for such confounders [41, 42].  
 
Circumferential margin involvement, in the UK, is defined by the Royal College of 
Pathologists criteria of tumour cells at or within 1mm of the resected margin [43]. 
However, in the USA, the definition is tumour present at the margin thus making the 
CRM rates inherently lower [30]. There is considerable controversy as to which definition 
is superior [44, 45]. Undoubtedly, the presence of tumour at the margin is associated with 
the worst prognosis [39]. However, it has also been shown that the intermediate group 
(tumour cells within 1mm but not at the margin) have a worse prognosis than patients 
with a margin greater than 1mm [42]. This has potentially important implications, as it 
could influence peri-operative treatment strategies, such as the use of radiation. It also 
makes the comparison of surgical series utilising different definitions of margin 
involvement difficult to interpret.  
 
Mandard tumour regression grade (MTRG) - Evidence of tumour response to 
chemoradiotherapy, as described initially by Mandard, has been shown to have 
significant prognostic value in oesophageal cancer [46]. Mandard tumour regression 
grade (MTRG) is a categorical scale between 1 (complete response) and 5 (no 
response) for the objective measurement of pathological response in samples of the 
primary tumour. MTRG has become a standard component of the reporting of 
oesophageal resection specimens in the UK, despite the fact that the score was 
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originally described for CRT rather than the widely practised chemotherapy. 
Nonetheless, numerous studies have supported its use and whilst other TRG’s have 
been proposed, none have superseded Mandard [47-49]. Some studies have utilised 3 
groups as opposed to 5 (MTRG 1, MTRG 2&3, MTRG 4&5). A further study that 
analysed survival and MTRG suggested that M3 naturally aligns with M4&5, and thus 
only patients exhibiting a significant response to NAC (<10% viable tumour) gain a 
survival advantage [50]. In this study the authors also assessed the relative importance 
of pathological response in the primary tumour to down-staging in regional lymph 
nodes. They demonstrated that 26% of patients had evidence of significant response in 
the primary tumour following NAC (MTRG 1&2), but when lymph node down-staging 
was also included, the total number of responders increased to 48%. The lymph node 
responders experienced improved disease free survival (DFS) compared to the non-
responders, irrespective of the Mandard score in the primary tumour. One explanation 
for this finding was that the smaller population of tumour cells within a lymph node may 
be more susceptible to the effects of chemotherapy, compared to the larger primary 
tumour. This study has potentially important implications both in terms of assessing 
lymph node response after NAC with staging modalities and also in the selection of 
patients who might benefit from adjuvant treatment, a subject which remains 
controversial.  
 
Acute phase proteins (Albumin / CRP) - There has been significant interest in the 
use of acute phase proteins as predictors of poor outcome in oesophageal cancer. A 
number of studies have suggested a low albumin and high CRP are associated with 
poor survival, although the exact mechanisms are unclear [51, 52]. It has been proposed 
that an aggressive, biologically active tumour may induce an acute phase response. 
Albumin may also fall in patients who are nutritionally compromised, and whilst the role 
of albumin as a marker of nutrition has been challenged, poor oral intake and 
significant weight loss have been shown to have a negative impact on survival [53]. 
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 Biological markers (EGFR, VEGF, HER) - A number of receptors are over-expressed 
in oesophageal cancer including those belonging to the EGFR family (EGFR, 
HER1,2,3), VEGF and Aurora kinases (AURKA). EGFR may be overexpressed in 30-
70% of oesophageal cancers [54-56], HER-2 in 19-43% [57] and VEGF in 30-60% [58], all 
associated with poor outcome. The prognostic role of these receptors and others such 
as E-cadherin and COX-2 has been reported in a number of meta-analyses [59-63]. 
 
Gene signatures - Gene expression profiling has allowed for the correlation of gene 
signatures with clinical and pathological outcomes in oesophageal cancer. One UK 
study demonstrated a 4 gene signature to strongly correlate with survival (p=0.0001) 
and this was independently prognostic in a multivariable model that adjusted for other 
known confounding factors (p=0.013) [64]. A further study from the US reported very 





1.2 Staging of oesophageal cancer 
  
The traditional diagnosis and staging of oesophageal cancer utilised endoscopy with 
biopsy and computed tomography (CT) to identify patients suitable for surgical 
resection. This approach often under-estimated the true extent of disease and, as a 
result, a significant proportion of patients underwent “exploratory” open and close 
surgery [66]. Improvements in technology, specifically the introduction of multi-detector 
CT, have enabled imaging at much higher spatial and temporal resolutions. As a result 
the sensitivity of CT has improved, with a meta-analysis of 20 studies suggesting 59% 
sensitivity for nodal status [67] and other studies quoting 37-66% for metastatic 
disease [68-70]. However, CT still struggles to accurately stage the primary tumour (T 
stage), has low discriminatory power for nodules below 1cm in diameter, and is poor at 
predicting response to neo-adjuvant chemotherapy [71, 72] .  
 
Additional staging modalities have emerged to compliment CT by providing a more 
detailed assessment of the primary tumour and surrounding lymph nodes. Endoscopic 
ultrasound (EUS) is more accurate than CT in assessing T stage and N status, the 
former because of its ability to delineate the layers of the oesophageal wall [38]. A meta-
analysis incorporating 2558 patients from 49 studies demonstrated EUS to have a 
sensitivity and specificity of 81% and 99% respectively for T1 disease, 81% and 96% 
for T2, 91% and 94% for T3 and 92% and 97% for T4 disease [73]. It can identify contact 
between the primary tumour and adjacent structures such as the trachea, aorta, 
pericardium or diaphragm and in doing so provide important information regarding 
resectability. A tumour length of greater than 5 cm on EUS, predicts T3 (or greater) 
disease with sensitivity, specificity, PPV and NPV of 89%, 92%, 89% and 92% 
respectively [74]. For early tumours, EUS may identify patients suitable for endoscopic 
resection. However, it struggles to distinguish Tis from T1a/b disease and hence EMR 
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continues to have an important diagnostic role to play in the selection of these patients 
for surgery, by providing a histological specimen for analysis [75].  
 
 
Fig. 3 The oesophageal wall is visualized as 5 alternating layers of differing echogenicity by 
EUS. The first layer is hyperechoic (white) and represents the superficial mucosa (epithelium 
and lamina propria). The second layer is hypoechoic (black) and represents the deep mucosa 
(muscularis mucosa). The third layer is hyperechoic and represents the submucosa. The fourth 
ultrasound layer is hypoechoic and represents the muscularis mucosa. This layer (muscularis 
propria) is critical in differentiating T1, T2, and T3 cancers. The fifth ultrasound layer is 
hyperechoic and represents the peri-oesophageal tissue. The thickness of the EUS layers is not 
equal to the thickness of anatomic layers[38]. (Reprinted with permission, Cleveland Clinic 
Centre for Medical Art & Photography 2001–2012. All Rights Reserved.) 
 
Other original studies and meta-analyses have shown the sensitivity and specificity of 
EUS for N stage may exceed 80% [67, 73, 76]. This may be further improved by the use of 
fine needle aspiration (FNA), reaching 96% in one study [73]. EUS can also assess the 
number of regional lymph nodes (LNs) in line with the requirements of the TNM 7 
classification, and this predicts survival [77-79]. As with any dynamic investigation, EUS is 
subject to inter-observer variation, although accuracy is improved when performed by 
endoscopists in high volume centres [80]. Additionally it may not be possible in patients 
with stenotic tumours, with one study suggesting that this occurred in 6% of patients 
and was sub-optimal in a further 14% [72].  Such strictures, however, are highly 
predictive of advanced disease [74, 81]. 
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The introduction of Positron emission tomography (PET) imaging has attracted 
significant interest as it provides a biological assessment of the tumour based on the 
uptake of fluoro-deoxy-glugose (FDG). PET has an improved sensitivity for metastatic 
disease and has been shown to up-stage 15% of patients to M1 disease who were 
previously being considered for radical treatment [82-84]. A meta-analysis of PET imaging 
demonstrated a sensitivity of 67% and specificity of 97% for metastatic disease 
although the yield for lesions below 1cm in diameter was poor [85]. Other studies have 
shown even more impressive results for PET at detecting metastases (sensitivity, 
specificity and accuracy of 88%, 93% and 91% respectively). PET appears to be better 
than CT for assessing distant metastases, in one study correctly up-staging 62% of the 
patients with metastases who had previously undergone a (false) negative CT scan [69]. 
All of the metastases missed by PET were less than 1cm.  
 
The development of PET/CT with its ability to correlate anatomical and functional 
tumour characteristics has further improved staging accuracy, such that it is now 
considered more accurate than CT at staging the local tumour [86] and distant 
metastases [68, 87]. One limitation in the early experience of PET imaging was that 
uptake in the primary tumour obscured local lymph nodes [88, 89]. Whilst EUS was said 
to provide a more accurate nodal assessment in this scenario, modern PET/CT has 
somewhat mitigated this problem [89]. A meta-analysis of PET imaging in the 
assessment of N stage has shown sensitivity and specificity of 59% and 81% 
respectively [67]. A recent study has demonstrated nodal disease on PET/CT at 
diagnosis to be a significant adverse prognostic marker [90].  
 
Numerous biological parameters measurable by PET have been reported as prognostic 
in oesophageal cancer. These include standardised uptake variable (SUV), mean 
tumour volume (MTV), total lesion glycolysis (TLG) and tumour heterogeneity [91]. 
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Metabolic uptake has been shown to differ significantly between AC and SCC [83]. 
Recent interest has also focussed on the measurement of tumour heterogeneity on 
PET as a surrogate for aggressive tumour biology and response to chemotherapy [92].  
 
As a result of these promising results, PET/CT has been widely adopted in the UK in 
the initial assessment of oesophageal cancer, and in some centres, in the re-staging of 
tumours following chemotherapy.  
 
The role of staging laparoscopy is somewhat controversial. Studies have suggested 
that the addition of laparoscopy changes management in 10% of patients (2% who 
were initially over-staged and therefore could proceed to surgery, 8% with previously 
undetected M1 disease [93]. Others have suggested sensitivities for liver and peritoneal 
disease of 86% and 71% respectively, concluding that laparoscopy may change 
management in as many as 17% of patients [94]. It is currently recommended for gastric 
and junctional carcinomas, but not for primary oesophageal carcinomas, based on the 
likelihood of metastatic disease below the diaphragm. However, it has been argued 
that the improved sensitivity of modern multi-slice CT and the addition of PET, may 
nullify the additional benefit of staging laparoscopy. Given the requirement for general 
anaesthetic, as well as the associated risks of laparoscopic surgery, its role in 
oesophageal carcinomas remains limited to selected patients.  
 
Magnetic resonance imaging (MRI) has attracted significant interest due to its improved 
soft tissue resolution compared to CT. As in the staging of rectal cancer, where MRI is 
now a standard investigation, it has the potential to improve local staging as well as 
margin prediction in patients with oesophageal cancer being considered for surgery. 
Initial studies showed mixed results, with a sensitivity, specificity and accuracy for T 
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stage of 40%, 63% and 25-60% respectively and for N stage 25-58%, 67-88% and 56-
72% respectively [95-97]. However, a subsequent study showed the accuracy of MRI to 
be much improved (81% for T stage and 63% for N status) [98]. Nodal staging may be 
significantly improved by the use of short inversion time inversion-recovery turbo spin-
echo (STIR TSE) MRI  with sensitivity, specificity, PPV and NPV of 81%, 98%, 93% 




1.3 Neo-Adjuvant Oncological treatment  
 
1.3.1 Neo-adjuvant chemotherapy - rationale for systemic therapy 
The rationale for systemic therapy in adenocarcinoma of the oesophagus lies in the 
natural history of the disease, where most patients present with evidence of nodal or 
systemic metastases. Even those patients offered “curative” surgery die predominantly 
of metastatic disease, presumably due to the presence of occult micro-metastases at 
the time of surgery [32, 100]. Studies evaluating this phenomenon have demonstrated 
tumour cells in the bone marrow of patients undergoing resection in 40-65% of 
cases [101-103]. Even in patients deemed to be N0, further pathological analysis may 
demonstrate lymph node micro-metastases in 30% of patients [104, 105]. This presumably 
explains the poor results in historical series of surgically treated patients prior to the 
adoption of neo-adjuvant chemotherapy (NAC).  
 
The perceived benefits of systemic chemotherapy include down-staging of the primary 
tumour [106] and the elimination of micro-metastases [107], supported by a number of 
studies showing reduced local and systemic recurrence [108-110]. However, a significant 
proportion of patients do not respond to NAC, and some develop progressive disease 
whilst on neo-adjuvant treatment. These latter tumours have poor biology and it is 
doubtful they were ever curable by surgery. Indeed, one might argue that these 
patients have avoided major futile surgery by undergoing chemotherapy which allows a 
time period for unfavourable tumours to declare themselves. In contrast, patients 
responding well to chemotherapy have a good long term prognosis. 
 
Three large randomised trials have shown a survival benefit for NAC in oesophageal 
cancer [109-111]. The largest trial (OEO-2) randomised 802 patients to 2 cycles of 
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Cisplatin and 5 Fluorouracil (CF) followed by surgery or surgery alone, demonstrating 
significantly improved R0 resection rates in the NAC group (60 vs 54% p<0.0001) and 
improved overall survival (5year survival  23% vs 17% p=0.03) [111, 112]. A further UK 
based trial (MAGIC) predominantly recruited patients with gastric cancer, however 26% 
of patients with junctional tumours were also included and randomised to peri-operative 
chemotherapy (epirubicin, cisplatin and 5 fluorouracil - ECF) and surgery or surgery 
alone [109]. It demonstrated a significant survival benefit for chemotherapy (5 year 
survival 36% vs 23% p=0.009). A randomised trial from France (FFCD) recruited 224 
patients to peri-operative CF and surgery or surgery alone, demonstrating an improved 
5 year overall survival (38% vs 24% p=0.02) and disease free survival (DFS) (p=0.003) 
with chemotherapy [110]. In contrast to MAGIC, this latter trial was comprised of 
predominantly lower oesophageal and OGJ tumours (75%), however the benefits of 
chemotherapy in terms of survival and recurrence rates were strikingly similar. Notably, 
in both trials, completion of adjuvant chemotherapy was poor, with only 50-65% of 
patients commencing chemotherapy following surgery and even fewer (42-50%) 
completing it.  
 
Whether peri-operative chemotherapy offers improved outcomes compared to a solely 
neo-adjuvant strategy remains contentious. Although OEO-2 demonstrated a survival 
benefit for NAC, this conflicted with the results of two other trials (RTOG 8911 and 
EORTC 40954) both of which failed to show any survival advantage for neo-adjuvant 
chemotherapy, despite improved surgical resection rates [113, 114]. Meta-analyses, 
subsequently confirmed an overall survival benefit for NAC [115, 116]. Interestingly, the 
benefit for chemotherapy appeared to be driven by the AC sub-group (HR 0.78 CI 0.64-
0.95 p=0.014) rather than SCC sub-group (HR 0.88 CI 0.75-1.03 p=0.12)[117]. Complete 
pathological response may be found in 2.5 – 13% of patients following NAC and these 
patients have excellent 5 year survival [109]. 
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In the UK, chemotherapy practice has evolved to reflect the results of these trials. NAC 
with CF was widely adopted following the successful completion of OEO-2, and this 
was expanded to 6 cycles of the peri-operative ECF regimen with the publication of the 
MAGIC trial. Subsequently, the demonstration that 5FU could be successfully replaced 
by the oral fluoro-pyramidine capecitabine in a RCT, led to ECX (epirubicin, cisplatin 
and capecitabine) largely replacing ECF [118]. Whether this additional neo-adjuvant 
chemotherapy translates into a survival benefit is currently being investigated in a 




1.3.2 Neo-adjuvant chemo-radiotherapy  
The rationale for neo-adjuvant chemo-radiotherapy (NACRT) is based on the sensitivity 
of oesophageal tumours to radiation and the principle of radio-sensitization, whereby 
chemotherapy augments the effects of radiotherapy leading to synergistic DNA 
damage and  inhibition of cell repair [119]. A number of trials have demonstrated a 
survival benefit following NACRT [3, 120] and although they were not without significant 
flaws, this practice was widely adopted in in North America, Australasia and parts of 
continental Europe. Most notable was the study by Walsh and colleagues which 
demonstrated a significant survival advantage for NACRT and surgery over surgery 
alone (3 year survival 32% vs 6%) although this study was heavily criticised for the very 
poor survival in the surgery alone group and the inadequacy of staging [3]. A further 
randomised trial recruited 56 patients with AC or SCC to NACRT followed by surgery or 
surgery alone [120]. Despite closing early, due to poor accrual, the authors reported a 
survival benefit for NACRT (5 year survival 39% vs 16%). However, an Australasian 
trial randomised patients with AC and SCC to NACRT and surgery or surgery alone 
(62% AC 38% SCC) showing no difference in OS or DFS. Sub-group analysis 
suggested that patients with SCC had better DFS than AC with this approach (HR 0.47 
vs 1.02) [121]. A number of other trials have failed to show any benefit for NACRT [122-125]. 
However, a subsequent meta-analysis supported the use of CRT as did a review of 
meta-analyses [117, 126].  
 
The publication of the CROSS trial, which randomised 366 patients (75% AC; 23% 
SCC) to NACRT and surgery or surgery alone, demonstrated a survival advantage for 
NACRT (OS 49 vs 24 months p=0.003) [127]. The overall benefit was strongly driven by 
the improved survival in the SCC sub-group (p=0.007), whilst the adjusted HR for AC 
did not reach statistical significance (p=0.07). CPR rates were 30%, again favouring 
SCC patients (CPR 49% SCC vs 23% AC) and complete surgical resection rates 
reached an impressive 93%. Anastomotic leak rates were 22% and 30% in the tri-
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modality and surgery alone groups respectively, raising questions as to the adequacy 
of surgery. The authors concluded that NACRT should be the standard of care for 
oesophageal cancer. However, the amalgamation of AC and SCC patients as well as 
the presence of a surgery alone control arm, remain overt weaknesses of this 
influential study.  
 
The impact of this trial on UK practice remains to be seen. Certainly, the current 
philosophy of treating resectable lower oesophageal SCC with NAC followed by 
surgery has been challenged by the results of CROSS, which convincingly suggests 
that these patients may benefit most from tri-modality therapy.  
 
However, the argument for AC is less convincing owing to the reduced sensitivity of 
these tumours to radiotherapy (XRT), the higher rates of systemic metastases in AC 
patients (compared to SCC which is more loco-regional [22]) and the much less 
convincing results from the CROSS trial in the AC sub-group.  
 
One criticism of NACRT regimens is the compromise in systemic chemotherapy 
delivery that such treatment entails. Certain chemotherapy drugs, such as epirubicin, 
are contraindicated with concurrent XRT and others require a dose reduction. Attempts 
to maintain chemotherapy doses with XRT, as adopted in the Walsh trial (CF), resulted 
in a regimen with high levels of toxicity. The significantly lower radio-sensitising doses 
of chemotherapy employed in the CROSS trial are considered inadequate by 
proponents of chemotherapy, who argue that the logic for a reduction in systemic 
therapy is fundamentally flawed, given that adenocarcinoma is predominantly a 
systemic disease. They stress that this regimen is only suitable for localised radio-
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sensitive tumours, such as those found in the SCC sub-group, which unsurprisingly 
skewed the overall survival benefit seen in the CROSS trial. 
 
Study Platinum Fluoropyrimidine Other 
CROSS Carboplatin AUC2 x 5  Paclitaxel 50mg/m2 x 5 
MAGIC total Cisplatin 360mg/m2 5FU 25200mg/m2 Epirubicin 300mg/m2 
MAGIC 
neoadjuvant 
Cisplatin 180mg/m2 5FU 12600mg/m2 Epirubicin 150mg/m2 
FFCD total Cisplatin 600mg/m2 5FU 18200mg /m2  
FFCD 
neoadjuvant 
Cisplatin 300mg/m2 5FU 9600mg/m2  
 
Fig. 4 Summary of systemic chemotherapy delivery in major trials. The equivalent Carboplatin 
dose to that employed in the MAGIC trial (Cisplatin 60mg x 3) is AUC4 and for FFCD (Cisplatin 
100mg x 3) it is AUC 5/6. In MAGIC, the Cisplatin dose was reduced to accommodate the 
additional Epirubicin. A three weekly “systemic” Paclitaxel dose is 200mg.  For comparison, the 
equivalent total chemotherapy dose would therefore be Carboplatin AUC 4  plus Paclitaxel 
200mg x 6 plus Epirubicin (MAGIC)or Carboplatin AUC 5/6 plus Paclitaxel 200mg x 6 
(FFCD)both of which represent much higher doses of chemotherapy than the radio-sensitizing 
AUC 2 plus Paclitaxel 50mg x 5(CROSS). Reproduced with permission EC Smythe 
  
 
Despite high CPR rates of 30% following NACRT, the majority (78%) of patients 
suffering a recurrence following this treatment, do so with systemic metastases. This 
pattern may be independent of the degree of response seen in the primary tumour on 
pathological analysis [128]. In a cohort study specifically assessing outcomes in patients 
with a CPR after NACRT, 5 year survival was only 50% with over 75% of the 
recurrences being systemic [129]. The authors highlighted a local recurrence rate of 13% 
as justification for the pursuit of local control with XRT, however the inadequacy of 
systemic therapy in a group of patients with no residual primary tumour was arguably 
the most important finding of this study. The principle that measures to improve local 
control do not necessarily translate into a survival advantage was also demonstrated in 
the MUNICON II trial [130]. In this prospective study, PET was used to identify non-
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responders to NAC, with these patients being diverted to CRT prior to surgery. This led 
to an improvement in pathological tumour regression, but interestingly no reduction in 





1.3.3 Studies comparing NAC to NACRT 
A number of studies have attempted to compare NAC and NACRT with conflicting 
results [131-133]. An important distinction should be made between the different NACRT 
regimens which vary in their delivery of chemotherapy. Some use concurrent 
chemotherapy and XRT with a radio-sensitizing dose of chemotherapy (CROSS), 
whilst others use sequential induction chemotherapy followed by CRT, with the greater 
total exposure to chemotherapy that this entails. Stahl et al adopted this latter 
philosophy and randomised 126 patients with AC from 19 centres to NAC/surgery or 
induction chemotherapy/CRT/surgery [131]. Although this study was underpowered, 3 
year survival showed a non-significant trend towards improved survival in the tri-
modality group (3 year survival 47 vs 27% p=0.07). Notably, this group had significantly 
fewer patients with N0 disease, a difference which could not be explained by local 
down-staging as tumour regression scores were similar between the groups. As these 
patients were not matched for clinical nodal status before randomisation, this raised the 
possibility that the CRT group had earlier stage disease from the outset.  Although only 
patients under 70 years of age with a WHO classification of 0 or 1 were considered for 
this trial, in hospital mortality was high following CRT (10.2% vs 3.8% p=0.26), some 
might argue unacceptably so. Other criticisms of this trial included the low accrual, the 
merger of oesophagectomy and gastrectomy patients and the high number of centres 
required to recruit a small volume of patients.   
 
A further Australasian trial recruited 75 patients to receive neo-adjuvant chemotherapy 
or chemoradiotherapy prior to surgery [132]. Both regimens utilised similar doses of 
chemotherapy. Despite higher rates of pathological response following NACRT (major 
response 8% vs 31% p=0.01) 5 year survival was similar (36% vs 45% p=0.60), 
leading the authors to acknowledge the high rates of systemic disease that determined 
most patients’ outcomes. 
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A single institution comparison of NAC versus NACRT showed no overall or disease-
free survival difference, and no reduction in local recurrence following CRT, despite 
higher rates of CPR (17% vs 4%) in this group. The authors noted higher complication 
rates (48% vs 33%, p=0.09) and mortality (6% vs 0% p=0.12) following NACRT [133].  
 
In a large meta-analysis, 24 studies were analysed incorporating 4188 oesophageal 
cancer patients [134]. These trials consisted of NAC vs surgery alone (9 trials; 1981 
patients), NACRT vs surgery alone (12 trials; 1854 patients) and NAC vs NACRT (2 
trials; 194 patients and 1 cohort study; 159 patients). Notably, the results of the MAGIC 
trial were excluded from analysis as it was not possible to differentiate those patients 
treated for junctional (oesophageal) cancers as opposed to gastric cancers. The HR for 
all-cause mortality, using surgery alone controls, was 0.87 for NAC (95% CI 0.79 – 
0.96 ; p=0.005) and 0.78 for NACRT (95% CI 0.70 – 0.88; p<0.0001). Both 
adenocarcinomas and squamous cell carcinomas were included in this overall analysis. 
Interestingly, the overall significance for NAC was driven predominantly by the AC sub-
group (HR AC 0.83; 95% CI 0.71 – 0.95 ; p=0.01), compared to the NACRT group 
which was driven by the improvements observed in the SCC sub-group (HR SCC 0.80; 
95% CI 0.68 – 0.93 ; p=0.004).  
 
In an attempt to compare NAC and NACRT, the authors pooled the data from the 2 
small trials that specifically examined this hypothesis (both described above and 
neither showing statistically significant results) with the remainder of the trials from the 
meta-analysis (none of which directly compared the two strategies). However, unlike 
the main results which distinguished AC and SCC, the pooled data did not adjust for 
these sub-groups. Hence, although the HR comparing NAC and NACRT (HR 0.88; 
95% CI 0.76 – 1.01; p=0.07) is often quoted by proponents of NACRT to favour this 
approach, its applicability to AC patients is questionable at best. The significant 
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heterogeneity of neo-adjuvant chemotherapy regimens in both arms was a significant 
confounder that could not be adjusted for within the remit of this study. 
 
A further consideration in deciding the optimal neo-adjuvant treatment strategy is the 
morbidity and mortality created by the addition of XRT to chemotherapy. In a fragile, 
nutritionally deplete group of patients, NACRT may be poorly tolerated, with the quoted 
mortality of this treatment alone averaging 3% (range 0-15%), higher than the post-
operative mortality reported in many surgical series. Those progressing to surgery may 
have higher rates of respiratory complications, anastomotic dehiscence, fistulation [123, 










1.3.4 Biological therapies 
The over-expression of numerous receptors in oesophageal cancer has led to a 
therapeutic interest in the targeting of these receptors with biological agents. A number 
of trials have investigated the use of Bevacizumab (an Antibody against VEGF) in 
unresectable AC [142, 143] showing improved survival. The idea that VEGF expression 
may be increased by NAC makes it a particularly attractive target in this setting. 
Trastuzamab (an Antibody to HER-2) has been combined with Cisplatin and Paclitaxel 
in advanced AC, with an OS of 24 months, supporting a role for HER-2 inhibition in 
these patients [144].  
 
 
Fig. 6 The EGF receptor family is a group of receptor tyrosine kinases that result in activation of 
the JAK/STAT, RAS/RAF, and PKC pathways. Bevacizumab is a VEGF inhibitor. Cetuximab, 
matuzumab, and panitumumab inhibit the EGF receptor at the ligand-binding site, while 
trastuzumab inhibits the HER-2 receptor via the same mechanism. Erlotinib, gefitinb, and 
lapatinib inhibit the tyrosine kinase moiety for the EGF receptor, while vandetanib and brivanib 
have the same mechanism of inhibition for the VEGFR-2 receptor. Sunitinib inhibits the tyrosine 
kinase moiety for the VEGF and PDGF receptors. Sorafenib is a selective RAF kinase 
inhibitor [145]. (Reproduced with permission Springer science & business media) 
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The TOGA trial, although focussed on advanced gastric cancer, also showed a benefit 
for Trastuzamab in combination with CF both in terms of OS (13.5 vs 11 months 
p=0.005) and PFS [146]. The RTOG0436 trial (NCT 00655876) amongst others has 





1.3.5 On-going and future trials 
The results of a number of on-going randomised trials will further inform decision-
making. The OEO-5 trial has compared 2 cycles of neo-adjuvant CF to 4 cycles of 
ECF, with the intention of defining the role of additional neo-adjuvant chemotherapy in 
oesophageal cancer. The STO-3 trial (NCT00450203) recruited over 1000 patients, 
randomising to peri-operative chemotherapy with or without Bevacizumab in operable 
oesophago-gastric adenocarcinoma. This trial, which finished accrual in 2013, also 
included a feasibility study assessing lapatinib (EGFR Tyrosine Kinase Inhibitor) in 
HER-2 positive cancers.  
 
The MAGIC vs CROSS Trial (NCT01726452) is an on-going RCT that aims to compare 
NAC, according to the MAGIC trial regimen, and NACRT using the CROSS regimen to 
identify which groups, if any, may benefit from trimodality therapy. 
 
The CRITICS trial (NCT00407186) was designed to assess the role of adjuvant chemo-
radiation in the context of modern systemic therapy regimens. It compares peri-
operative ECX (3 cycles before and after surgery) to neo-adjuvant ECX (3 cycles), 
followed by adjuvant CRT. 
 
The TOXAG study (NCT01748773) is assessing the role of trastuzamab in addition to 
CRT in the adjuvant setting for HER 2 positive gastric and OGJ tumours. A further trial 
based in the USA (NCT01196390) is adding Trastuzamab to neo-adjuvant CRT 
(paclitaxel and carboplatin). 
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The CALGB group (NCT 01333033) have initiated a study aiming to recruit 200 
patients with OGJ tumours to undergo NAC followed by a PET scan performed after 
cycle 3. Non responders on PET (<35% reduction in SUV) will cross over to concurrent 
CRT with the primary intention of achieving a CPR in 20% of these “non-responding” 





1.4 Re-staging after chemotherapy 
 
With the widespread adoption of neo-adjuvant chemotherapy for oesophageal cancer 
in the UK, many studies have attempted to assess the accuracy of staging modalities 
at predicting response to such treatment. Tumour assessment following neo-adjuvant 
therapy may be considered as two different entities, the first being TNM re-staging to 
provide an anatomical tumour stage following chemotherapy. The second is an 
estimation of response to NAC that aims to predict pathological tumour regression. 
Traditionally, the latter has provided a qualitative assessment of the tumour with 
questionable decision-making value. More recently, attempts at quantifying such 
response have led to a more standardised objective approach, incorporating 
anatomical and physiological parameters.   
 
Endoscopy and re-biopsy have a sensitivity of 60% and 36%, specificity of 34% and 
100%, PPV of 49% and 100% and NPV of 44% and 24% respectively in predicting 
pathological response after CRT [149].  
 
Staging after chemotherapy remains challenging as most modalities, particularly CT 
and EUS, struggle to differentiate viable tumour from fibrosis. The presence of an 
oesophageal stent can also make this staging assessment particularly unreliable. 
Historically, CT assessment has been poor at re-staging tumours following NAC and 
NACRT. Various methods of quantifying tumour response on CT have been proposed, 
the commonest being the RECIST (Response evaluation criteria in solid tumours) 
criteria where tumour size is used to categorize tumours into complete response, 
partial response, stable disease or progressive disease [150, 151]. CT volume assessment 
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has also been used, with volume change correlating with pathological response in 
some studies [152] but not others [153].  
 
A comprehensive literature review compared CT with EUS and PET in the assessment 
of tumour response to chemotherapy showing CT accuracy (54%) to be inferior to both 
EUS (86%; p=0.003) and PET (85%; p=0.006) [72]. Other studies have confirmed CT to 
be less accurate than EUS and PET for both early and late assessment of response to 
NAC [71]. 
 
EUS may have the ability to predict pathological response but published studies have 
been inconsistent with the quoted sensitivity, specificity and accuracy ranging from 50-
100%, 36-100% and 67-100% respectively [154]. In a meta-analysis of EUS, the 
accuracy of re-staging for T stage and N status was 58% and 62% respectively [72, 154]. 
A number of single institution series have concluded that EUS is of limited benefit in the 
re-staging of oesophageal cancer, mainly due to difficulties in assessing T stage and 
identifying complete responders to NAC [155]. However, most showed EUS to perform 
better at nodal re-staging and response assessment. A prospective study of 41 patients 
compared cross-sectional area changes on EUS following CRT, to Mandard TRG [156]. 
Twenty out of 23 (87%) pathological responders had evidence of an endoscopic 
response and 10/13 (77%) non-responders on definitive pathology had no endoscopic 
response (PPV 80%; NPV 81%).  
 
The addition of FNA to EUS may improve the reassessment of N stage, reaching 78% 
in one study [157]. Others have successfully utilised EUS and FNA to identify residual 
nodal disease after NACRT (sensitivity 82%, accuracy 68%), despite concerns over 
false positive results caused by traversing the primary tumour to reach the target lymph 
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node [158, 159].  Given the importance of nodal disease on overall prognosis, and 
particularly persistent nodal disease following chemotherapy, this represents an 
interesting finding.  
 
It may be concluded, on the basis of currently available evidence, that EUS struggles to 
identify T stage after NAC, but may be useful in N staging and overall response 
assessment, both of which are arguably more important from a prognostic 
perspective [154]. Despite this, EUS is not commonly performed after NAC in the UK. 
 
PET has been widely studied in the prediction of response to neo-adjuvant 
chemotherapy. Numerous PET parameters have been used to assess response to 
therapy including standardised uptake variable (SUV), mean tumour volume (MTV), 
total lesion glycolysis (TLG) and tumour heterogeneity. In a review of the literature, 
most studies showed that a reduction in SUV following NAC predicted pathological 
response [160-164]. In some studies this physiological response on PET also translated 
into a survival benefit. In a meta-analysis of 13 studies, the pooled sensitivity of PET for 
response assessment after NAC was 70.3% with a specificity of 70.1% [165]. A 
subsequent study showed even better sensitivity, specificity and accuracy of PET 
response prediction reaching 86,93 and 90% respectively [160]. 
 
PET response may be assessed early following commencement of chemotherapy (e.g. 
after the first or second cycle of treatment) or may be delayed until after the completion 
of neo-adjuvant therapy [166]. It has been proposed that early and late PET imaging may 
examine slightly different facets of response [167]. The former has the theoretical 
advantage of providing an earlier insight into the response of the tumour to 
chemotherapy, potentially expediting a change in strategy in the absence of a 
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response. Delayed PET may assess residual tumour following completion of 
therapy [167, 168]. In a review of the literature, early PET assessment (reduction in SUV) 
after cycle 1 of chemotherapy predicted response in all six studies, whereas delayed 
PET did so in only 2 out of 6 studies. The authors concluded that early PET response 
assessment was preferable to delayed imaging [164].  
 
Prospective studies, including the MUNICON trial, have shown that a reduction in SUV 
at 14 days following commencement of NAC predicts pathological response and 
survival [160, 169, 170]. In this study, the authors used a PET based algorithm to divert 
patients to early surgery in the absence of a response to chemotherapy [170].  
 
One of the criticisms of the many studies evaluating PET response to chemotherapy 
has been the significant heterogeneity encountered in the patient groups. For example, 
the inclusion of adenocarcinomas and squamous cell carcinomas, the use of different 
NAC regimens and even the use of XRT in sub-groups makes data interpretation 
difficult. PET may be more unreliable following NACRT due to the profound 
inflammatory reaction created by this treatment [171]. Other studies have lacked 
consensus in terms of their definition of pathological response and the cut-offs used to 
define PET response. Some have proposed a 35% reduction in SUV as distinguishing 
responders from non-responders [170]. Further studies suggested a 50% reduction in 
SUV after NAC predicted DFS, down-staging (sensitivity 78%, specificity 53%, PPV 
57%, NPV 75%) and pathological response (sensitivity 90%, specificity 45%, PPV 
24%, NPV 96%) [172]. Other studies have contradicted this finding entirely, showing no 
relationship between PET parameters and survival, recurrence or pathological 
response [173]. The lack of consistency in the literature was highlighted by a systematic 
review on PET response which did not proceed to meta-analysis due to significant 
heterogeneity in the dataset [174].  
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As a result, alternative parameters measurable by PET imaging have also been 
assessed. Tumour volume change after CRT, calculated according to a 40% threshold 
from maximum SUV, correlated with pathological response whereas other parameters 
including SUV did not [175]. PET heterogeneity may also predict response better than 
SUV and with new markers emerging all the time, this is a rapidly evolving field. Even 
allowing for study variations, the consensus remains that PET/CT provides the best 
available evaluation of tumour response to NAC and it is therefore surprising that this 
has not been adopted as standard in the UK [157]. 
 
Multi-parametric MRI has the potential to improve chemotherapy response 
assessment, although published studies are generally small. Compared to CT, it can 
provide a multi-functional assessment of the tumour and superior soft tissue 
characterisation, without exposure to radiation.  
 
Dynamic contrast-enhanced MRI (DCE-MRI) uses the flow of gadolinium contrast 
between blood vessels and the extra-cellular space to quantify tumour perfusion and 
permeability [176]. Following NAC, tumour vasculature may return to normal such that 
the porosity of blood vessels decreases, thus reducing the extravasation of contrast 
into the extracellular space [177]. Radiation may induce the opposite effect due to the 
release of pro-angiogenic factors [178, 179].  
 
Blood oxygenation level dependent (BOLD) MRI measures tumour oxygenation using 
the differing magnetic characteristics of oxygenated and de-oxygenated haemoglobin 
(Hb) [180]. Tumour oxygenation may increase in patients who are responding to NAC 
due to improved vascularisation and tumour perfusion [181].  
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Diffusion weighted (DW) MRI assesses the diffusion of water molecules within a given 
tissue. Cellular structures may restrict diffusion and the ability to measure this 
phenomenon provides a surrogate for cellularity. Apparent diffusion coefficient (ADC) is 
a measureable parameter that reflects and quantifies this principle. Hence areas of 
high cellularity have a low ADC and vice versa [182]. It has been hypothesised that ADC 
should increase in those patients who are responding well to NAC as a result of 
treatment induced cell death. 
  
A prospective study investigated the ability of diffusion weighted MRI to predict 
pathological response following the neo-adjuvant treatment of OGJ tumours [183]. This 
study recruited 32 patients, predominantly with AC (81%), who had been treated with 
NAC or NACRT. Mandard TRG was used to quantify pathological response. Pre- and 
post-treatment DW-MRI scans were used to compare ADC and tumour volumes. 
Tumour volume parameters were unable to predict pathological response. However, a 
low initial ADC value and a significant increase in ADC during chemotherapy predicted 
pathological responders with sensitivity, specificity, PPV, NPV, accuracy and AUC of 
88%, 87%, 88%, 87%, 88% and 0.909, respectively. Thus, the authors concluded that 
ADC may have a role in predicting pathological response in oesophageal cancer.  
 
A further study compared DW-MRI and PET/CT in early response assessment 
following NAC [184]. 15 patients with OGJ tumours underwent both imaging modalities 
on the same day, before and after treatment. High levels of concordance (73%) were 
found between changes in ADC and SUV. Absolute ADC values were also significantly 
different between pathological responders and non-responders (p=0.043).  
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Taken together, these studies justify the further evaluation of MRI in oesophageal 
cancer staging. It has shown promise in local tumour staging, margin prediction, the 
assessment of nodal status and the prediction of response to neo-adjuvant treatment, 
although it remains to be seen whether it improves decision making over and above 
currently available staging modalities. However, it may be that MRI can provide, in one 
staging assessment, the equivalent information to that currently available from multiple 
investigations and may therefore have the potential to simplify staging algorithms. 
 
Imaging heterogeneity is a technique which quantifies the intensity and distribution of 
pixels within a given image [185]. Entropy and uniformity are the baseline parameters 
that comprise heterogeneity, with preliminary evidence suggesting a prognostic role in 
oesophageal cancer [186-188].  In a retrospective study of 31 patients who received NAC, 
change in heterogeneity predicted survival (36 months vs. 11 months, p<0.001) [186]. A 
further study showed a significant correlation between CT heterogeneity parameters 
and PET SUV in 21 oesophageal cancer patients [188]. Another study evaluated the role 
of PET heterogeneity in 41 patients who underwent definitive CRT [92]. PET 
heterogeneity (sensitivity 76-88%, specificity 73-91%) appeared to predict treatment 
response more accurately than SUV (sensitivity 53-71%, specificity 45-73%). Hence 
heterogeneity, measured on both CT and PET based imaging, may predict survival and 
could be used as an adjunctive tool in treatment response assessment. 
 
With on-going developments in imaging technology, the optimal re-staging algorithm 
has yet to be fully defined. A significant challenge is how to implement multiple staging 
investigations, within an already complex pathway, without over-burdening the patient 
with tests. A further consideration is how to improve staging accuracy whilst at the 
same time adhering to the recommended guidelines for initiation of treatment that exist 
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in the UK. This time constraint already puts significant pressure on the patient pathway 





1.5 Treatment of oesophageal cancer 
 
1.5.1 Surgery 
The role of radical surgery in oesophageal cancer is controversial, as it has been in the 
treatment of many other tumour types. In part this is due to the different philosophies of 
treating cancer, one of which mandates a radical operation to remove the tumour with 
wide margins, including all regional lymph nodes, with “curative” intent. The more 
pragmatic approach is to regard surgery to remove the primary tumour as one 
component of a multi-modality strategy, on the basis that oesophageal cancer often 
represents a systemic disease at presentation. As such, tumour response to systemic 
therapy primarily dictates the prognosis in all but the earliest tumours. 
 
Historically, radical surgery was widely adopted in the management of breast cancer, 
resulting in mutilating operations for questionable benefit. The advent of targeted 
systemic and hormonal therapies as well as the long terms results of trials have 
demonstrated this radical approach to be of little benefit. As a result, breast conserving 
surgery as opposed to mastectomy is now offered to most women with breast cancer 
and sentinel node sampling has largely replaced axillary clearance in the management 
of regional lymph nodes [189-191]. Both of these policies are supported by extensive 
scientific evidence in favour of a less radical approach. Indeed, more recent data 
suggest that patients with confirmed metastatic disease in a sentinel node may not 
benefit from axillary surgery at all, on the basis that local recurrence is rare and may 
not be reduced by axillary clearance anyway [192]. 
 
51
Oesophageal cancer due to its propensity for metastatic dissemination has a worse 
outlook than breast cancer and it is therefore logical that the majority of patients will 
require systemic therapy. Surgery in isolation is seldom indicated, a principle supported 
by historical series which have rarely demonstrated 5 year survival to exceed 20% with 
this approach [123, 193, 194].  Current guidelines recommend that only T1 tumours should 
be managed by primary surgery and even a proportion of these patients may be 
suitable for endoscopic resection [195]. Given that peri-operative systemic therapy is 
recognised as a standard of care for most patients with oesophageal cancer, it is 
surprising that contemporaneous randomised trials have continued to include surgery 
alone control arms [127].  
 
Transhiatal oesophagectomy (THO) involves abdominal and cervical incisions, with 
abdominal and lower mediastinal lymphadenectomy performed under direct vision and 
an anastomosis sited in the neck. Its proponents argue that the avoidance of a 
thoracotomy reduces the rate of post-operative complications, and that an anastomotic 
leak in the neck has significantly less morbidity and mortality than a leak in the 
mediastinum [4, 196, 197]. Transthoracic oesophagectomy (TTO) involves a 2-stage 
procedure, incorporating abdominal and thoracic components which facilitate 
dissection of the tumour under direct vision and a more extensive mediastinal 
lymphadenectomy. Access may be achieved via the right or left chest, the former being 
the most common.  
 
Extended lymphadenectomy undoubtedly improves staging accuracy [198] but whether it 
improves loco-regional disease control or overall survival remains contentious. The 
most influential study to examine the number of lymph nodes required to adequately 
classify N status concluded that 12 lymph nodes resulted in a 90% sensitivity [199]. A 
further study concluded that 15 lymph nodes were required to provide sufficient staging 
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information and that this translated into a survival advantage [200]. Based on worldwide 
data, a further study proposed criteria for an adequate lymphadenectomy based on 
tumour T stage (T1 : 10 lymph nodes, T2 : 20 lymph nodes, T3/4 : 30 lymph 
nodes) [201]. However this recommendation far exceeds the average US experience of 
lymphadenectomy, reported as 13 lymph nodes by the American College of surgeons 
study group [202].  
 
How much of the perceived benefit of radical surgery is due to the focus on achieving 
an R0 resection, as opposed to radical lymphadenectomy is also the subject of much 
debate [203]. Either way, the choice of incisions should not be confused with radicality, 
as the presence of a thoracotomy per se does not guarantee a “radical” approach to 
the primary tumour has been performed [204]. Standardisation of surgical technique has 
undermined many studies that have attempted to address the role of surgical radicality 
in oesophageal and gastric cancer [205]. 
 
Most studies analysing more versus less radical oesophageal cancer surgery have 
failed to demonstrate any survival benefit for a more radical approach. The principal 
RCT to address this question showed higher rates of morbidity following radical surgery 
(TTO) with no benefit in terms of overall survival [206]. At five year follow-up, sub-group 
analysis, although underpowered, suggested that some groups may benefit from the 
more radical transthoracic approach, namely oesophageal (as opposed to junctional) 
tumours and those patients with a limited number of involved lymph nodes(1-8 
nodes) [207]. Other randomised trials [208-210], meta-analyses [4, 211-213] and case series 
have demonstrated similar survival following transhiatal and transthoracic resection. 
The question of whether morbidity is increased by the addition of a thoracotomy is also 
somewhat contentious with a number of studies suggesting higher mortality and 
respiratory morbidity [4, 213, 214]. Other studies have contradicted this finding, and indeed 
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some complications such as recurrent laryngeal nerve (RLN) palsy and anastomotic 
stricture are more common after THO [212, 213]. 
 
 
Fig. 7 Lymphadenectomy fields in oesophageal cancer surgery. Published in Companion to 
specialist surgical practice – oesophago-gastric surgery 2013. SM Griffin. Reproduced with 
permission Elsevier 2014 
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The principle of radical surgery has been extended further in Japan to include 3 field 
lymphadenectomy i.e. cervical node dissection in addition to the abdominal and 
mediastinal lymphadenectomy typically performed during transthoracic surgery. The 
rationale for extended resection was prompted by reportedly high rates of isolated 
tumour recurrence in the neck following transthoracic surgery for SCC [215]. In a small 
RCT of 62 patients, 2 field and 3 field lymphadenectomy were compared, showing no 
difference in survival or recurrence but a higher rate of complications in the 3 field 
group [216]. The authors emphasised a trend towards survival improvement with the 3 
field approach as justification for adopting this approach. However, the data from Japan 
almost exclusively consists of patients with SCC, making any application to western 
patients difficult to interpret. As a result, 3 field lymphadenectomy for western patients 
with adenocarcinoma has not been widely accepted and the 2 field Ivor-Lewis 






1.5.2 Minimally invasive oesophagectomy (MIO) 
Whilst the short term mortality following oesophageal resection has fallen considerably 
in recent years, it remains an operation with high rates of morbidity and a significant 
impact on quality of life. This has inevitably heralded a search for minimally invasive 
approaches to the oesophagus and enhanced recovery programmes to minimise the 
surgical insult [217, 218]. MIO has been successfully adopted in high volume units, but 
remains a technically challenging procedure with a prolonged learning curve. In a 
report of over 1000 MIO procedures performed in a single unit, in-hospital mortality was 
1.7% with a median hospital stay of 8 days and comparable oncological outcomes to 
open surgery [219]. Early reports of the successful implementation of MIO prompted a 
prospective, multi-institution study showing low rates of mortality (<2%) and an overall 
survival of 50% at 3 years [220]. Numerous other studies have compared open surgery 
to MIO [221-223]. In a recent systematic review of 1100 patients, MIO was associated with 
reduced blood loss, reduced morbidity and reduced hospital stay compared to open 




1.5.3 Barrett’s surveillance and Endoscopic mucosal resection for early cancer 
With the recognition of the role of Barrett’s oesophagus in the development of 
oesophageal adenocarcinoma and the introduction of endoscopic surveillance 
programmes for such patients, there has emerged a cohort of patients with HGD and 
intra-mucosal adenocarcinoma in whom a therapeutic dilemma exists. Whilst surgery 
offers excellent long term survival for these patients, the morbidity and mortality 
associated with oesophagectomy might be considered excessive, given the low 
probability of lymph node metastases in early tumours [225, 226]. This has led to the 
search for viable alternatives such as endoscopic mucosal resection (EMR) and 
endoscopic sub-mucosal dissection (ESD). Based on the assumption that early 
disease (≤ T1a) can be accurately identified by currently available staging modalities, 
EMR allows for resection of early tumours with low morbidity and mortality [226]. Whilst 
long term results are awaited, the undoubted advantages in a correctly selected group 





1.5.4 Definitive Chemo-radiotherapy 
Alternatives to surgical resection for oesophageal cancer are appealing for obvious 
reasons. Herskovic (RTOG 85-01) published the seminal study analysing definitive 
CRT vs XRT alone demonstrating significantly improved OS and DFS in the CRT arm, 
albeit with high rates of local recurrence (47%) [227]. Other studies have reported 
encouraging survival results following definitive CRT, rivalling those for surgery, stage 
for stage [228, 229]. Elderly patients, particularly those with SCCs treated by CRT, had 
improved outcomes compared to best supportive treatment in one study, and 
comparable survival to surgery in another, strengthening the argument for non-
operative management in this sub-group of patients [228, 230]. In a further trial assessing 
the role of high dose versus low dose radiotherapy in SCC (INT 0123) no benefit was 
seen with increased radiation [231]. Indeed, for most patients with SCC, primary CRT 
with salvage surgery for those patients with residual or recurrent cancer, appears to be 






1.5.5 Adjuvant treatment 
The evidence for adjuvant therapy is less convincing for oesophageal cancer as indeed 
it has been for other tumours such as rectal cancer. In principle, it does not share some 
of the perceived advantages of neo-adjuvant treatment, namely the guaranteed early 
delivery of systemic therapy with the potential to down-stage the primary tumour and 
improve surgical resection margin rates. In rectal cancer, only patients who responded 
to neo-adjuvant treatment gained any benefit from adjuvant chemotherapy in one 
study [233]. Whilst this may be intuitive, little evidence currently exists to guide adjuvant 
therapy in oesophageal cancer. 
 
In the US, the Macdonald study (INT 0116) [234] demonstrated a benefit for adjuvant 
CRT (36 months vs 27 months p<0.01), although 80% of patients recruited had gastric 
cancer and only 10% of patients had a D2 resection. Therefore, the criticism levelled at 
this trial was that CRT compensated for inadequate surgery. Trials assessing adjuvant 
chemotherapy (as opposed to neo-adjuvant or peri-operative treatment) have largely 
failed to show an overall survival advantage for this approach [235, 236]. However, the 
relative improvement in survival seen with peri-operative chemotherapy (MAGIC, 
FFCD) compared to a solely neo-adjuvant strategy (OEO-2) is taken by some, as 
indirect evidence of a benefit for adjuvant treatment.  
 
The impact of peri-operative chemotherapy may be considerable, with toxicities related 
to the treatment and on-going nutritional deficiencies providing multi-disciplinary 
challenges. The fact that over 50% of patients recommended for adjuvant 
chemotherapy in the aforementioned randomised trials did not complete their 
treatment, emphasises the enormous cumulative physical insult of multi-modality 
therapy. The addition of XRT almost certainly adds to this overall morbidity. Whether 
patients with minimal response to chemotherapy on pathological analysis should be 
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offered adjuvant treatment, and the role of changing chemotherapeutic agents in this 




1.5.6 Quality of life after oesophageal cancer surgery  
The recovery from oesophageal cancer surgery is prolonged and extends far beyond 
the date of discharge from hospital. Numerous quality of life studies have concluded 
that the resolution of physical symptoms and restoration of emotional well-being may 
take up to three years following surgery [237, 238]. Some functions will never return to 
baseline. Post-operative complications are known to adversely affect QOL and 
survival [239]. With the benefit of hindsight, any patient not surviving long enough to 
regain their pre-operative QOL, would have been better served by alternative 
oncological therapies to surgery [240]. This “break-even” point for patients undergoing 




1.5.7 Recurrence after oesophageal cancer surgery 
The likelihood of recurrence after oesophageal cancer surgery is predominantly 
determined by the stage of the tumour at the time of resection. Loco-regional 
recurrence may occur in the tumour bed, regional lymphatics or at the anastomotic site, 
the latter often precipitated by an involved margin at the time of surgery. Distant 
metastatic recurrence most frequently occurs in the liver and lungs although numerous 
other sites have been described. Although termed “recurrence”, these metastases were 
most likely present, albeit undetectable, at the time of surgery.  
 
The timing of recurrence tends to be mainly within the first 2 years from surgery, and is 
a devastating outcome for a patient still recovering from extensive treatment. Distant 
metastases tend to present earlier than loco-regional recurrences, possibly related to 
poor tumour biology or, alternatively, the insidious onset of local symptoms from the 
mediastinum [241]. Adenocarcinomas have a greater tendency to metastasise 
systemically than SCCs, which have a more loco-regional pattern of dissemination, 
frequently affecting the mediastinal and cervical lymph nodes [23, 24, 198, 242].  
 
Historically, routine surveillance imaging for the detection of recurrence has not been 
indicated due to the lack of available second line treatment options. However, the 
increasing recognition of biological markers and the availability of targeted therapies for 
tumours expressing these markers may justify a change in approach. That said, 
disease recurrence after surgery is seldom cured and in the absence of effective 
second line therapy, the emphasis of treatment is to manage symptoms and maintain 






One of the major challenges in oesophageal cancer management is the acquisition of 
high volume data which can provide a baseline for standards of care and the guidance 
of new management strategies. Whilst most advances in oncological therapies are 
guided by the results of multi-centre randomised trials, many research questions are 
not feasible to address in such trials. Therefore, the results of large institutional cohort 
series remain important as they reflect true working practice, and may address several 
research questions simultaneously. 
 
The aim of this thesis was to consolidate and analyse a large prospectively collected 
database of oesophageal resections with a view to assessing :- 
1. Factors associated with early recurrence and death after oesophageal cancer 
surgery 
2. The role of surgical radicality in the management of oesophageal cancer 






These studies utilised a database of 680 consecutive oesophageal resections 
performed over a ten year period (2000-2010). This involved a research collaboration 
between two high volume institutions (St Thomas’ hospital and Royal Marsden 
hospital) based in London, United Kingdom. All surgeries were performed with curative 
intent for malignant or pre-malignant tumours of the oesophagus or oesophago-gastric 
junction (type 1 and 2 according to Siewert’s classification). Tumours with an epicentre 
greater than 2cm distal to the true junction were regarded as Type 3 and thus excluded 
from analysis. Staging and management principles were very similar between the two 
units, and incorporated OGD, CT, EUS and latterly PET in the initial assessment of 
these tumours. Patients with OGJ tumours underwent additional laparoscopy. Patients 
deemed eligible for a radical treatment pathway were then considered for primary 
surgery or neo-adjuvant chemotherapy. Re-staging after NAC utilised CT (thorax, 
abdomen & pelvis) but not routinely EUS or PET. Surgery was performed or supervised 
by three surgeons. Surgical approach included transhiatal or transthoracic resection, 
the latter subdivided into left thoraco-abdominal or Ivor-Lewis resections, primarily 
dictated by surgeon preference. Pathological analysis was performed by one member 
of a dedicated team of histopathologists. Staging utilised the 7th edition of the TNM 
classification. 
 
The database, initiated in 2000, was prospectively maintained and included all patients 
undergoing surgery for oesophageal cancer between 2000 and 2010. Data were 
rigorously cross-referenced with all available sources to ensure accuracy. These 
included prospective hospital databases, hospital records (notes and lab records),  
cancer registry and GP (General Practitioner) records to ensure long term outcome 
data were robust. Three major STH database reviews were conducted during this 
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period (2003, 2006 and 2010) whereby pathological and outcome data were checked 
and cross-referenced. Some additional fields were added to the database during this 
process with these fields requiring retrospective data supplementation. On each 
occasion the reviews were performed by two independent researchers. The RMH 
database was also independently verified in 2011 by a professional data collector. 
Missing data was pursued rigorously, driven by the prospective decision to exclude 
patients from multi-variable analysis if more than one data field was missing. Survival 
was updated in May 2012, according to the last confirmed attendance to a hospital or 
GP practice.  
 
Recurrence was defined as radiological or histological evidence of disease as agreed  
by multi-disciplinary team consensus. This was further sub-divided into loco-regional 
(confined to the anastomosis, tumour bed or lymph nodes considered local to the 
original site of the primary tumour e.g. mediastinum or left gastric territories), distant 
(haematogenous, peritoneal or distant lymph node spread) or both.  
 
Data analysis was performed with the assistance of an experienced bio-statistician 
from an aligned academic unit at Karolinska Institutet, Stockholm, Sweden and was 
independently verified. Prior to the commencement of each studies’ statistical analysis 
a manual cross-checking process performed by two data managers ensured the 
database had not been corrupted. Analysis utilised SAS (version 9.2 SAS Institute Inc., 
Cary, NC, USA). 
 
Ethical approval for use of the database was granted by the Integrated research 
application system (IRAS reference : 12-NW-0511). 
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From the outset, the intention was to submit this thesis by publication route. It therefore 
incorporates three manuscripts, each containing their own specific introduction, 
methods, results and conclusion sections. Each study used a separate prospective 
study protocol (Appendix) agreed by the authors before any statistical analyses were 
performed. Whilst some deviations from protocol were made at the request of journal 
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Background: Accurate selection of patients for radical treatment of esophageal cancer is essential to avoid early recurrence and death (ERD) after
surgery. We sought to evaluate a large series of consecutive resections to assess factors that may be associated with this poor outcome.
Methods: This was a cohort study including 680 patients operated for esophageal cancer between 2000 and 2010. The poor outcome group
comprised 100 patients with tumor recurrence and death within 1 year of surgery. The comparison group comprised 267 long‐term survivors, deﬁned
as those surviving more than 3 years from surgery. Pathological characteristics associated with poor outcome were analyzed using logistic regression
to determine odds ratios (OR) and 95% conﬁdence intervals (CI).
Results: On the adjusted model T stage and N stage predicted poor survival, with the greatest risk being patients with locally advanced tumors and
three or more involved lymph nodes (OR 10.6, 95% CI 2.8–40.0). Poor differentiation (OR 2.8, 95% CI 1.4–5.5), chemotherapy response (OR 3.6,
95%CI 1.2–10.6), and involved resectionmargins (OR 2.7, 95%CI 1.2–6.0) were all signiﬁcant independent prognostic markers in the multivariable
model. There was a trend toward worse survival with lymphovascular invasion (OR 2.0, 95%CI 0.9–4.2) and low albumin (OR 1.9, 95%CI 0.8–4.4)
but not of statistical signiﬁcance in the adjusted model.
Conclusions: Esophageal cancer patients with poorly differentiated tumors and three or more involved lymph nodes have a particularly high risk of
ERD after surgery. Accurate risk stratiﬁcation of patients may identify a group who would be better served by alternative oncological treatment
strategies.
J. Surg. Oncol. 2014;109:459–464.  2013 Wiley Periodicals, Inc.
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INTRODUCTION
Early tumor recurrence and death within 1 year of esophagectomy for
esophageal cancer must be considered a failure of accurate pre‐operative
staging and patient selection. Tumor recurrence is the leading cause of death
in patients undergoing esophageal cancer resection, with the majority
recurring within 1 year of surgery [1–3]. In order to justify an extensive
therapeutic insult such as esophagectomy, there should be a reasonable
prospect of improving duration of survival with acceptable quality of life.
Patients who do not survive a minimum of 1 year after surgery, rarely
regain their pre‐operative levels of activity or quality of life [4–7]. These
patients, therefore, need to be identiﬁed before surgery as they would
often be better treated by other therapies.
A number of factors are known to be associated with poor prognosis
in esophageal cancer, but unfortunately many of these are only
conﬁrmed after resection of the specimen, limiting their practical use at
the time of surgical decision‐making [8]. Accurate prediction of
chemotherapy response remains elusive, and there is not currently a
reliable method of determining suitability for surgery.
The aim of this study was to assess clinicopathological factors
associated with early recurrence and death (ERD) within 1 year of
surgery for esophageal cancer.We evaluated a large series of consecutive
resections, where the ERD group was compared to a group of long‐term
survivors (LTS). To our knowledge this is the ﬁrst such study to
speciﬁcally assess early esophageal cancer recurrence inwestern patients.
METHODS
Study Design
This was a cohort study based on two prospectively collected
databases from St. Thomas’ Hospital and Royal Marsden Hospital, both
high‐volume units for esophageal cancer surgery in London, United
Abbreviations: CI, conﬁdence interval; CT, computed tomography; CPR,
complete pathological response; CRP, C‐reactive protein; ERD, early
recurrence and death; EUS, endscopic ultrasound; FDG‐PET, ﬂuorodeox-
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Kingdom. Included in the source study cohort were 680 consecutive
patients who underwent surgical resection of esophageal or esophago‐
gastric junction (Type I or II) tumors with curative intent during the
period 2000–2010 inclusive. The follow‐up ended in March 2012.
The two comparison groups were those with tumor recurrence and
mortality within 1 year of surgery (ERD) and those who survived at least
3 years from operation (LTS). Three years was chosen on the basis that
few patients suffer from tumor recurrence after this period [9]. The
minimum follow‐up period was 12 months allowing every patient to be
potentially eligible for the ERD group.
Clinical Management
Patients underwent a standard protocol of investigation, including
esophago‐gastro‐duodenoscopy, computed tomography (CT), endoscopic
ultrasound (EUS), and ﬂuorodeoxyglucose positron emission tomography
(FDG‐PET). Chemotherapy practice evolved during the period of study,
and followed standard indications and regimens supported by randomized
trial data [10,11]. Thismeant that patientswith T2 tumors (or greater) and/or
node positive disease on initial staging were considered eligible for
induction therapy. All patients weremanaged by a recognized upper gastro‐
intestinal cancer multi‐disciplinary team (MDT).
Surgical resections included transthoracic (n¼ 412) and transhiatal
(n¼ 268) esophagectomies with choice of approach determined by
individual surgeon preference.
Histological staging of the resected specimens was standardized to
meet the updated 7th Edition TNM criteria to allow for comparison [12].
Follow‐Up
At the time of updating the database, survival was recorded according
to the last conﬁrmed attendance to a hospital or general practitioner (GP)
clinic. Tumor recurrence was assessed by way of histological or
radiological conﬁrmation of disease, as agreed by the MDT.
Statistical Analysis
Unconditional logistic regression was used to calculate odds ratios
(OR) and 95% conﬁdence intervals (CI). Crude and multivariable
analysis was performed. The variables included in the multivariable
model were: age (<56, 56–69,>69 years old), pathological tumor stage
(T0‐2 N0/1/2‐3, T3‐4 N0/1/2‐3), tumor grade (moderately or poorly
differentiated), response to chemotherapy (complete pathological
response (CPR), good—moderate response and poor—no response,
no chemotherapy and unknown response [patients had chemotherapy
but Mandard score not documented]), margin status (R0, R1/2),
lymphovascular invasion (positive/negative) and pre‐operative albumin
(<40, 40). Patients were excluded from the model if they had one or
more missing variable (n¼ 8). The additional discrepancy in patient
numbers between Tables I and II was accounted for by the perfect
correlation of HGD, CPR, and well‐differentiated tumors with LTS.
Our initial intention was to include albumin and C‐reactive protein
(CRP) in the main multivariable model but due to the lack of available
data from the early study period this would have resulted in loss of
statistical power. Sufﬁcient numbers of patients had albumin data to be
included in a smaller model that included all of the above parameters.
CRP was not entered into multivariate analysis. All analyses were
performed using SAS, version 9.2 (SAS Institute, Inc., Cary, NC).
RESULTS
Patients
Among all 680 patients in the source study cohort, the overall
survival at 1 year was 80% with estimated survival (Kaplan–Meier) of
57% and 45% at 3 and 5 years, respectively. In‐hospital mortality was
2%.
The ERD group comprised 100 patients who died within 12 months
of surgery with proven recurrence, while the LTS group included 267
patients (Fig. 1).
The pattern of early recurrence in the ERD group was loco‐regional
(18%), distant metastases (57%) or both (25%), while in the LTS group,
late recurrence was more likely to be loco‐regional (40%), although
metastatic (38%) and combined recurrences (22%) were still common.
Time to recurrence was shorter in patients with metastatic disease (5
months) than loco‐regional relapse (6 months).
Characteristics
Age, sex, and histological sub‐type were similar between the groups
(Table I). The ERD group contained a higher frequency of more
advanced tumors with a greater burden of nodal disease and higher grade
of tumor differentiation. A greater proportion of patients underwent peri‐
operative chemotherapy in the ERD group (ERD 84% vs. LTS 56%)
reﬂecting their more advanced disease. More patients had incomplete
resections in the ERD group (ERD R0 19% vs. LTS R0 74%) with
almost all (96%) of these R1 resections due to involvement of the
circumferential resection margin, deﬁned as tumor at or within 1mm of
the radial margin. Lymphovascular invasion was more likely in the ERD
group (ERD 70% vs. LTS 25%) as was a low pre‐operative albumin
(ERD 57% vs. LTS 43%) and raised pre‐operative CRP (ERD 55% vs.
LTS 31%). Length of post‐operative hospital stay was similar between
the groups (ERD 16 days vs. LTS 15 days). Post chemotherapy CT in the
ERD group demonstrated progressive disease in 4 patients, stable
disease in 36 patients, partial response in 40 patients and no visible
disease in 4 patients. Sixteen patients did not undergo chemotherapy.
Risk of Early Recurrence and Death
Older age did not strongly inﬂuence the OR of ERD (Table II).
Pathological tumor stage was strongly associated with ERD, with the
greatest OR encountered in patients with locally advanced tumors (T3–
T4) and in those with three or more involved lymph nodes (OR 10.6;
95% CI 2.8–40.0). Other adverse prognostic features included
pathological tumor grade, where poor differentiation heralded an
adjusted OR of 2.8 (95% CI 1.4–5.5) compared to moderately
differentiated tumors.
Poor histological response to chemotherapy (adjusted OR 3.2; 95%
CI 1.1–8.8) and positive margin status (adjusted OR 2.7; 95% CI 1.2–
6.0) were independent predictors of ERD. The point OR estimates
showed worse survival with lymphovascular invasion (adjusted OR 2.0;
95% CI 0.9–4.2) and pre‐operative albumin (OR 1.9, 95% CI 0.8–4.4),
but they were not statistically signiﬁcant. To minimize the cohort
heterogeneity, further analysis was performed excluding the patients
with squamous cell carcinoma, but no impact on the overall results or
independent prognostic features was found after such exclusion (data not
shown).
DISCUSSION
This study indicates that pathological tumor stage, tumor grade,
completeness of resection, and poor response to chemotherapy are
independent indicators of ERD after esophageal cancer surgery, while
albumin and lymphovascular invasion might also be predictors of such
outcomes.
The novelty of the present study is mainly its design. We have
speciﬁcally sought to identify those factors associated with a clearly
deﬁned outcome sufﬁciently poor, that it could guide decision‐making,
speciﬁcally the avoidance of surgery. This is the ﬁrst study to assess this
in a cohort of western patients with adenocarcinoma.
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Somemethodological issues deserve attention. The study allowed for
the long‐term follow‐up of a large series of consecutive esophageal
cancer resections. The comparison of a worst outcome group of patients
with a good outcome group made the outcomes distinct. Moreover, the
ability to adjust the results for relevant prognostic factors was an
advantage. Finally, although the sample size of the cohort was large, the
study did not have statistical power to verify weak or moderate
associations.
A potential bias is the selection of cases to the two referral hospitals
for esophageal cancer surgery. However, staging and management
principles were similar and there were no major differences in post‐
operative mortality or stage‐matched survival. The cohort’s
heterogeneity in terms of operative approach was countered by the
fact that surgical strategy (transhiatal or transthoracic esophagectomy)
did not have any impact on survival or recurrence (data not shown).
Additionally, the principle of treating adenocarcinoma and squamous
cell carcinoma as distinct pathological entities was adhered to by the
conﬁrmation that our results were unchanged by the exclusion of
squamous carcinomas on subsequent analysis.
A large study from China assessed early recurrence after resection for
squamous cell carcinomas of the esophagus, concluding similar markers
of adverse prognosis to those found in our study [1]. Approximately 52%
of the recurrences in their series were metastatic disease with the
remainder being local or regional.
Our series almost exclusively focused on adenocarcinoma and 82%
of patients recurring and dying within 12 months of surgery had
metastatic disease. The timing and pattern of disease recurrence is of
interest as it provides an insight into the mechanism of failure. Our study
clearly suggests that the most signiﬁcant obstacles to good patient
selection for surgery are the identiﬁcation of occult metastases and how
to measure response to treatment by accurately re‐staging patients after
chemotherapy. CT appears unable to discriminate patients with a very
poor outcome after surgery as evidenced by the fact that nearly half of the
patients in the ERD group had some evidence of tumor regression on
their post‐chemotherapy scan. This would suggest that alternative re‐
staging modalities such as PET‐CT should be further assessed after
chemotherapy with the ability to assess physiological response to
treatment. This modality has the added beneﬁt of improved sensitivity
for the detection of occult metastases.
Of particular interest is to identify high‐risk patients based on the
information that could realistically be available at the time of surgical
decision‐making. Improved loco‐regional staging is essential given the
clear importance of T stage and N stage on the overall prognosis. T stage
can be predicted with an accuracy of greater than 80% on EUS [13,14],
but this test is less useful in predicting tumor downstaging after
chemotherapy due to its inability to differentiate tumor from
ﬁbrosis [15,16]. Potential advances may be brought about by future
improvements in CT, EUS, andmagnetic resonance imaging (MRI). The
latter may also have a role in predicting circumferential resection margin
involvement [17,18].
Nodal status, and particularly patients with multiple (3) lymph
nodes involved do particularly poorly but, despite its importance, it
TABLE I. Demographics and Tumor Characteristics of the Study Patients Who Had Undergone Resection for Esophageal CancerWith Early Recurrence &
Death or Long‐Term Survival (Alive 3 Years After Surgery)
Early recurrence and death Long‐term survivors
n % n %
Number of patients 100 — 267 —
Age (mean (range)) 62 (28–81) — 62 (32–81) —
Male: female 78:22 78:22 214:53 80:20
Adenocarcinoma: squamous 89:11 89:11 206:35 85:15
Chemotherapy (%) 84 84 150 56
Tumor stage
T0‐2 N0 5 5 127 48
T0‐2 N1 5 5 34 13
T0‐2 N2‐3 10 10 15 5
T3‐4 N0 9 9 51 19
T3‐4 N1 15 15 21 8
T3‐4 N2‐3 56 56 19 7
Grade (differentiation)
CPR 1 1 15 6
HGD 0 0 23 9
Well 0 0 16 6
Moderate 41 41 156 58
Poor 58 58 57 21
Chemotherapy response
Complete 1 1 15 6
Good/moderate 9 9 60 22
Poor/no response 48 48 39 15
No chemotherapy 16 16 117 44
Unknown response 26 26 36 13
Margin status
R0 19 19 195 74
R1/2 81 81 70 26
Lymphovascular invasion
Negative 29 30 195 75
Positive 69 70 65 25
Albumin
Normal (40) 33 43 123 57
Abnormal (<40) 44 57 91 43
Hospital stay (median (range)) 16 (7–191) — 15 (7–127) —
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remains extremely difﬁcult to assess this accurately after neo‐adjuvant
treatment. The addition of EUS with ﬁne needle biopsies after
chemotherapy may have a further role to play in this respect although
this is not currently standard practice in our unit [19]. One study has
demonstrated EUS to have an accuracy of 68% and sensitivity of 82% at
determining nodal status after neo‐adjuvant chemoradiotherapy [20]. A
recent study has successfully utilized PET‐CT in the accurate evaluation
of nodal status after chemotherapy for squamous cell carcinoma and this
may well add discriminatory power to decision making prior to
surgery [21].
Poor differentiation on pathological tumor grading independently
tripled the likelihood of ERD compared to patients with moderately
differentiated tumors. Tumor grade can be predicted pre‐operatively
from endoscopic biopsies, and conﬁrmed poor differentiation cannot be
ignored as an ominous prognostic sign.
Chemotherapy response is perhaps the most important component of
patient selection. FDG‐PET has been widely championed as having a
role in response prediction, and even selecting patients for salvage
surgery in the absence of a response [22–25]. However, this has recently
been challenged by a prospective study which failed to correlate FDG‐
PET results after chemoradiotherapy with pathological response,
survival or recurrence [26]. It is therefore still unclear, whether
anatomical (re‐staging CT/EUS) or physiological (FDG‐PET)
assessment of tumor response is superior and whether indeed they
correlate with deﬁnitive response seen at pathological examination.
Albumin and CRP are of particular interest as they can be easily
measured pre‐operatively. Although our data have not been able to
fully assess these parameters, the latter not being included in
multivariable analysis, there does seem to be an association with poor
prognosis. Indeed, a number of studies have shown acute phase
proteins to be prognostic and as such they merit assessment in further
studies [27,28].
Circumferential margin status is prognostically important but
this may be affected by the criteria used to deﬁne a positive margin
[29,30]. Almost all (96%) of our R1 resections were related to CRM
involvement, which at 38% overall, is in line with other published series
after neo‐adjuvant chemotherapy using the RCP deﬁnition [31]. This, in
itself, identiﬁes an area for potential improvement and inevitably,
proponents of neo‐adjuvant chemoradiotherapy would argue that this
strategy may improve pathological response rates and reduce margin
involvement, albeit with greater potential morbidity [32–34].
It is tempting to select patients at risk of margin involvement for
escalation of neo‐adjuvant therapy, whilst sparing those patients who
may not beneﬁt the extra morbidity of radiation. We have developed a
predictive score for CRM involvement (data not shown) based on CT
characteristics that shows encouraging results (speciﬁcity 98%, positive
predictive value 86%) and could therefore be used in the context of our
multivariable model to predict poor outcome and/or select patients for
additional radiotherapy. It must also be remembered that the vast
majority of patients dying within a year of surgery, are doing so with
established metastatic disease suggesting that local control is not the
predominant issue in the worst outlook patients. As such, any neo‐
adjuvant regimen must strive to maintain maximal systemic efﬁcacy and
compromising this in the pursuit of local control may have an adverse
effect by lacking equivalent efﬁcacy for occult micrometastases.
In our series, the combination of a locally advanced (T3/4) poorly
differentiated adenocarcinoma, with three or more lymph nodes
involved, a low pre‐operative albumin and involved resection margin
TABLE II. Odds Ratios (OR) and 95% Conﬁdence Intervals (CI) of Early Recurrence and Death After Esophagectomy for Esophageal Cancer
Crude Adjusted
OR 95% CI OR 95% CI
Age (years)
<56 1 (Ref) – 1 (Ref) —
56–69 0.9 0.5–1.7 0.9 0.4–2.0
>69 1 0.5–2.0 1.3 0.5–3.3
Tumor stage
T0‐2 N0 1 (Ref) — 1 (Ref) —
T0‐2 N1 3 0.8–12.1 2.4 0.6–10.4
T0‐2 N2‐3 13 3.6–46.9 5.2 1.2–22.0
T3‐4 N0 3.7 1.1–12.8 1.6 0.4–6.1
T3‐4 N1 15.2 4.5–51.5 4.6 1.1–18.9
T3‐4 N2‐3 58.5 18.7–182.3 10.6 2.8–40.0
Grade (differentiation)
Moderate 1 (Ref) — 1 (Ref) —
Poor 3.8 2.3–6.3 2.8 1.4–5.5
Chemotherapy response
Good/moderate 1 (Ref) — 1 (Ref) —
Poor/no response 7.8 3.4–17.7 3.2 1.1–8.8
No chemotherapy 1.1 0.5–2.8 0.9 0.3–2.6
Unknown response 5.2 2.2–12.7 3.6 1.2–10.6
Margin status
R0 1 (Ref) — 1 (Ref) —
R1/2 9.8 5.4–17.6 2.7 1.2–6.0
Albumin
40 1 (Ref) — 1 (Ref) —
<40 1.8 1.0–3.2 1.9 0.8–4.4
Lymphovascular invasion
Negative 1 (Ref) — 1 (Ref) —
Positive 5.7 3.4–9.7 2 0.9–4.2
Adjusted for age, tumor stage, grade, chemotherapy response, margin status, albumin, and lymphovascular invasion.
1 (Ref)¼ reference value.
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resulted in a 75% risk of dying within 1 year and 85% risk within
18 months (almost all with recurrent cancer). This must be weighed
against a 6% chance of surviving 3 years from surgery, with no
signiﬁcant survival difference between patients with N2 and N3 disease
in this sub‐group of patients.Whether this outcome is sufﬁciently poor to
change practice is debatable but it may at least guide decision‐making. In
the absence of a clear response to treatment, it is difﬁcult to justify
surgery in this group of patients and perhaps themajority would be better
served by alternative treatment strategies.
Despite this, it remains difﬁcult to advise a patient with a technically
resectable tumor not to have surgery on the basis of a predicted outcome.
Molecular and biological markers may simplify this decision in the
future [35,36]. In the meantime, we can only attempt to individualize
therapy based on certain tumor characteristics, previous experience and
patient wishes. Given the high proportion of patients developing early
recurrence with metastatic disease, there needs to be renewed focus on
the pre‐therapeutic identiﬁcation of occult metastases.
In conclusion, this study has highlighted the importance of advanced T
stage (T3/4), N status (N2/3), and poor differentiation as markers of early
poor outcome. A rigorous multi‐disciplinary staging process should be
capable of predicting these parameters with reasonable accuracy. The
additional use of acute phase proteins and models to predict margin
involvement may further risk stratify a group of patients in whom careful
consideration must be given before embarking on surgery. Although
assessment of response to chemotherapy continues to pose signiﬁcant
challenges, there can at least be some optimism that a robust prognostic
scoring systemwith the ability to guide management strategy is achievable.
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Background: The optimal surgical approach to tumours of the oesophagus and oesophagogastric
junction remains controversial. The principal randomized trial comparing transhiatal (THO) and
transthoracic (TTO) oesophagectomy showed no survival difference, but suggested that some subgroups
of patients may benefit from the more extended lymphadenectomy typically conducted with TTO.
Methods: This was a cohort study based on two prospectively created databases. Short- and long-term
outcomes for patients undergoing THO and TTO were compared. The primary outcome measure was
overall survival, with secondary outcomes including time to recurrence and patterns of disease relapse. A
Cox proportional hazards model provided hazard ratios (HRs) and 95 per cent confidence intervals (c.i.),
with adjustments for age, tumour stage, tumour grade, response to chemotherapy and lymphovascular
invasion.
Results: Of 664 included patients (263 THO, 401 TTO), the distributions of age, sex and histological
subtype were similar between the groups. In-hospital mortality (1·1 versus 3·2 per cent for THO and
TTO respectively; P= 0·110) and in-hospital stay (14 versus 17 days respectively; P<0·001) favoured
THO. In the adjusted model, there was no difference in overall survival (HR 1·07, 95 per cent c.i.
0·84 to 1·36) or time to tumour recurrence (HR 0·99, 0·76 to 1·29) between the two operations. Local
tumour recurrence patterns were similar (22·8 versus 24·4 per cent for THO and TTO respectively).
No subgroup could be identified of patients who had benefited from more radical surgery on the basis
of tumour location or stage.
Conclusion: There was no difference in survival or tumour recurrence for TTO and THO.
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Introduction
The optimal surgical approach to tumours of the oeso-
phagus and oesophagogastric junction is controversial.
The debate centres principally on the philosophical prin-
ciples underlying the treatment of oesophageal cancer, one
of which mandates radical surgery with a level of lympha-
denectomy that maximizes locoregional control and pre-
vents the stepwise progression of disease. By deﬁnition,
this requires transthoracic oesophagectomy (TTO).
A more pragmatic approach is to regard all but the
earliest oesophageal cancers as a systemic disease at
presentation, in which case the prognosis is determined
predominantly by tumour biology. As such, surgery tailored
mainly to removal of the primary tumour is an adjunct to
the systemic therapy that will primarily dictate outcome.
In this context, transhiatal oesophagectomy (THO) should
not result in a survival disadvantage. Prediction of which
patients may beneﬁt from more extended surgery remains
unclear from the literature.
The principal randomized clinical trial1 to address this
issue did not show any overall survival advantage withmore
radical surgery. Subgroup analysis2, although underpow-
ered, did suggest a beneﬁt in some patients with a particular
level of lymph node involvement at the 5-year follow-up.
The present analysis involved a large cohort of
consecutive patients undergoing oesophageal resection
in whom the surgical approach, THO or TTO, was
dictated by surgeon preference, in order to assess the
role of radicality in oesophageal cancer surgery. It was
 2014 BJS Society Ltd BJS 2014; 101: 511–517
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hypothesized that more radical surgery (TTO) would
provide an oncological survival beneﬁt, on the basis
of more complete mediastinal lymphadenectomy, and
that extended dissection of perioesophageal tissue would
reduce the rate of margin involvement (R1 resection).
Methods
This was a cohort study based on two prospectively created
databases from St Thomas’ Hospital and Royal Marsden
Hospital, London, UK, involving consecutive patients
who underwent surgical resection of oesophageal or
oesophagogastric junction (Siewert type I or II3) tumours
with curative intent between 2000 and 2010. Follow-up
ended in July 2012. The primary outcome measure was
overall survival following the surgical approach of THO
or TTO. Secondary outcomes were time to tumour
recurrence and the pattern of such recurrence.
Study patients underwent a standard protocol of
investigation, including oesophagogastroduodenoscopy,
computed tomography of the thorax, abdomen and
pelvis, endoscopic ultrasonography and, since 2007,
ﬂuorodeoxyglucose positron emission tomography.
Chemotherapy practice evolved during the period of
study, and followed standard regimens supported by ran-
domized clinical trial data4,5. Indications for chemotherapy
were no different according to the unit of presentation
or type of surgical resection planned. All patients were
managed by a recognized upper gastrointestinal cancer
multidisciplinary team.
TTO comprised right-sided transthoracic with separate
abdominal phase (Ivor Lewis) and left thoracoabdominal
approaches. Some of the Ivor Lewis resections utilized a
laparoscopic abdominal phase. THO was performed via
roof-top and cervical incisions, and included transhiatal
dissection of the lower mediastinum under direct vision.
The operative approach was determined by individual
surgeon preference, with one surgeon performing either
transhiatal or left thoracoabdominal resections and two
surgeons performing Ivor Lewis resections exclusively.
Specimens were examined by dedicated upper gastroin-
testinal histopathologists in each unit. Histological staging
of the resected specimens was standardized to meet the
updated seventh edition of the tumour node metastasis
(TNM) criteria6 to allow for comparison.
Hospital mortality was deﬁned as any postoperative
death occurring before discharge from hospital. Patients
entered a follow-up protocol that included 3-monthly
clinic visits for the ﬁrst year with surveillance computed
tomography performed 3 and 6months after surgery.
Subsequently patients were reviewed every 6months for
5 years, with further imaging based on clinical features.
At the time of updating the database, survival was
recorded according to the last conﬁrmed attendance to
any hospital clinic, or, if discharged from surgical follow-
up, the date last seen by their general practitioner.
Tumour recurrence was assessed by histological or
radiological conﬁrmation of disease, as agreed by the
multidisciplinary team.
Statistical analysis
Cox proportional hazards models were used to calculate
hazard ratios (HRs) with 95 per cent conﬁdence intervals
(c.i.) for TTO compared with THO in relation to time
to death or time to tumour recurrence. Both times were
measured as continuous variables from the date of surgery.
THO was used as the reference category. Survival was
calculated by the Kaplan–Meier method.
Three models were used: a crude (unadjusted) model
(model 1); a main model that adjusted for age (con-
tinuous), pathological tumour stage (categorized as
T0N0, T1–2N0, T1–2N1–3, T3–4N0, T3–4N1 or
T3–4N2–3), tumour grade (well, moderately or poorly
differentiated), response to chemotherapy (complete
pathological response, good or moderate response, and
poor or no response representing Mandard tumour regres-
sion scores of 1, 2–3 and 4–5 respectively7, no chemother-
apy and unknown response (patient had chemotherapy
but Mandard score not documented)), and lymphovascular
invasion (positive or negative) (model 2); and an additional
model that further adjusted for margin status (R0 or R1/2)
and lymph node yield (less than 10, 10–19, 20–29, or 30
or more nodes) (model 3). These two additional prognostic
markers in model 3 were excluded from model 2 because
they were considered to represent a mechanism by which
radical surgery might provide a survival advantage.
A positive circumferential resection margin (CRM) was
deﬁned as tumour at or within 1mm of the radial margin
according to Royal College of Pathologists criteria8.
Lymph node yield was stratiﬁed according to previously
validated Worldwide Oesophageal Cancer Collaboration
(WECC) criteria9 (required lymph node yield: T1 tumour,
10 or more nodes; T2, 20 or more nodes; T3–4, 30 or
more nodes).
To evaluate the proportional hazards assumption, the
correlation between Schoenfeld residuals10, calculated
as the difference between observed and expected co-
variable values for each patient who died, and failure time
were tested. A non-signiﬁcant relationship between these
residuals and failure time supports the proportional hazards
assumption. Stratiﬁed analyses were performed one by
 2014 BJS Society Ltd www.bjs.co.uk BJS 2014; 101: 511–517
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one for tumour location (oesophageal, oesophagogastric
junction types 1 and 2), T category (‘early’, T1–2;
‘advanced’, T3–4) andN category (N0, N1, N2 andN3) to
see whether any association between surgical approach and
outcomewasmodiﬁed by particular tumour characteristics.
All data management and analyses were performed
using SAS version 9.2 software (SAS Institute, Cary,
North Carolina, USA). Data were analysed independently
by an experienced biostatistician at a separate academic
institution (Karolinska Institute, Stockholm, Sweden).
P< 0·050 was considered statistically signiﬁcant.
Results
The source cohort consisted of 680 patients, of whom
15 patients who did not have surgery for malignant or
premalignant disease, and one patient in the TTO group
who died during surgery before tumour resection were
excluded. Among the 664 patients included in the study
cohort, 263 (39·6 per cent) underwent THO and 401 (60·4
per cent) had TTO. TTO comprised Ivor Lewis (325
patients) and left thoracoabdominal (76) approaches. The
distributions for age, sex and histological subtype were
similar between the groups, although there was a tendency
towards more advanced tumour stage in the TTO group
(Table 1). A lower proportion of patients in the THO group
received neoadjuvant chemotherapy (47·1 per cent versus
78·1 per cent in the TTO group).
Postoperative outcomes
There were three in-hospital deaths (1·1 per cent) after
THO and 13 (3·2 per cent) after TTO (P = 0·110).
Median (range) hospital stay was signiﬁcantly shorter after
THO (14 (7–95) versus 17 (8–191) days; P< 0·001). In
total, 108 patients (41·1 per cent) in the THO group
developed tumour recurrence: locoregional in 32 patients
(12·2 per cent), metastatic in 48 (18·3 per cent), and both
locoregional and metastatic in 28 (10·6 per cent). This
compared to 179 patients (44·6 per cent) with recurrence
in the TTO group: locoregional disease in 40 patients
(10·0 per cent), metastatic in 81 (20·2 per cent), and both
locoregional and metastatic in 58 (14·5 per cent).
Overall survival was 80·2, 55·1 and 44·4 per cent at
1, 3 and 5 years respectively. Crude analysis indicated a
survival beneﬁt for THO, but in the adjusted model there
was no difference in overall survival between the groups
(HR 1·07, 95 per cent c.i. 0·84 to 1·36) (Table 2). Similarly,
there was no difference in time to tumour recurrence in
the adjusted model (HR 0·99, 0·76 to 1·29); however, when
additional adjustments were made for margin status and
Table 1 Demographics and tumour characteristics according to






Age (years)* 64(10) (29–83) 64(10) (34–84)
Sex ratio (M : F) 217 : 46 317 : 84
Histology
Adenocarcinoma 205 (77·9) 324 (80·8)
Squamous carcinoma 32 (12·2) 48 (12·0)
HGD 21 (8·0) 7 (1·7)
CPR 5 (1·9) 22 (5·5)
Tumour stage
T0N0 26 (9·9) 29 (7·2)
T1–2N0 70 (26·6) 91 (22·7)
T1–2N1–3 62 (23·6) 57 (14·2)
T3–4N0 35 (13·3) 64 (16·0)
T3–4N1 30 (11·4) 46 (11·5)
T3–4N2–3 40 (15·2) 114 (28·4)
Tumour grade
CPR, HGD, well differentiated 36 (13·7) 52 (13·0)
Moderately differentiated 143 (54·4) 217 (54·1)
Poorly differentiated 84 (31·9) 132 (32·9)
Chemotherapy response
Complete 5 (1·9) 22 (5·5)
Good or moderate 51 (19·4) 89 (22·2)
Poor or no response 57 (21·7) 160 (39·9)
Unknown response 11 (4·2) 42 (10·5)
No chemotherapy 139 (52·9) 88 (21·9)
Lymphovascular invasion
No 147 (55·9) 234 (58·4)
Yes 116 (44·1) 167 (41·6)
Margin status
R0 155 (58·9) 240 (59·9)
R1 106 (40·3) 158 (39·4)
R2 2 (0·8) 3 (0·7)
Lymph node yield
< 10 78 (29·7) 57 (14·2)
10–19 139 (52·9) 136 (33·9)
20–29 35 (13·3) 110 (27·4)
≥ 30 11 (4·2) 98 (24·4)
Death during follow-up
No 129 (49·0) 179 (44·6)
Yes 134 (51·0) 222 (55·4)
Recurrence during follow-up
No 155 (58·9) 222 (55·4)
Yes 108 (41·1) 179 (44·6)
Locoregional 32 (12·2) 40 (10·0)
Metastatic 48 (18·3) 81 (20·2)
Both 28 (10·6) 58 (14·5)
In-hospital mortality
No 260 (98·9) 388 (96·8)
Yes 3 (1·1) 13 (3·2)
Hospital stay (days)† 14 (11–20) (7–95) 17 (13–26) (8–191)
Values in parentheses are percentages unless indicated otherwise;
values are *mean(s.d.) (range) and †median (i.q.r.) (range). THO,
transhiatal oesophagectomy; TTO, transthoracic oesophagectomy;
HGD, high-grade dysplasia; CPR, complete pathological response; T,
tumour; N, node.
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Table 2 Multivariable analysis of time to death and tumour
recurrence following transhiatal (reference) and transthoracic
oesophagectomy for oesophageal cancer
Hazard ratio
n Time to death Time to recurrence
Model 1
All patients 664 1·35 (1·09, 1·68) 1·30 (1·02, 1·65)
Model 2
All patients 664 1·07 (0·84, 1·36) 0·99 (0·76, 1·29)
Adenocarcinoma alone 543 1·05 (0·81, 1·36) 0·98 (0·74, 1·30)
Left thoracoabdominal
excluded
588 0·97 (0·76, 1·25) 0·91 (0·68, 1·20)
Ivor Lewis radical
lymphadenectomy
429 0·83 (0·60, 1·14) 0·90 (0·64, 1·28)
Model 3
All patients 664 1·20 (0·93, 1·54) 1·04 (0·79, 1·37)
Values in parentheses are 95 per cent conﬁdence intervals. Model 1,
crude data; model 2, adjusted for age, tumour stage, tumour grade,
chemotherapy response and lymphovascular invasion; model 3, adjusted
as per model 2 plus margin status and lymph node yield.
lymph node yield (Table 2, model 3) a beneﬁt for THO was
seen, although the higher HR point estimate in the TTO
group was not statistically signiﬁcant (HR 1·20, 0·93 to
1·54). TTO showed a greater median lymph node yield
(20 versus 13 in the THO group; P< 0·001), but overall
rates of clear CRM involvement were similar (59·9 and
58·9 per cent respectively) (Table 1), albeit unadjusted for
the discrepancies in T category. Analysis of the subsets of
patients with T3–4 tumours indicated that clear margins
were more often achieved by TTO (40·2 per cent versus
30·4 per cent for THO; P = 0·065).
In stratiﬁed analyses of patients with adenocarcinoma,
no difference was seen between the operative approaches
for overall survival (HR 1·05, 95 per cent c.i. 0·81 to 1·36)
or time to recurrence (HR 0·98, 0·74 to 1·30) (Table 2).
To minimize potential selection bias, whereby some
patients with bulky junctional tumours were selected
for the left thoracoabdominal approach, an analysis was
performed excluding these patients from the TTO group.
Risk of mortality (HR 0·97, 95 per cent c.i. 0·76 to 1·25)
and tumour recurrence (HR 0·91, 0·68 to 1·20) remained
similar (Table 2), although the rate of clear CRMs in the
remainder of the TTO group (325 patients) increased to
65·2 per cent and the median lymph node yield increased
to 24.
To see whether radicality (as opposed to surgical
approach) improved outcomes, THO was compared with a
selected subgroup of TTO procedures that consisted only
of Ivor Lewis resections with radical lymphadenectomy
as per the WECC criteria9. This ‘radical TTO’ group
of 166 patients had a median lymph node yield of 31
Table 3 Multivariable analysis of transhiatal (reference) versus
transthoracic oesophagectomy for oesophageal cancer in relation
to time to death and time to recurrence, stratiﬁed by tumour
location, tumour category and node category
Hazard ratio
Model n Time to death Time to recurrence
Tumour location
Oesophagus 1 175 1·61 (0·95, 2·75) 1·52 (0·86, 2·71)
Oesophagogastric
junction
Type 1 1 261 1·21 (0·87, 1·67) 1·21 (0·84, 1·74)
Type 2 1 228 1·58 (1·12, 2·23) 1·45 (0·98, 2·13)
Oesophagus 2* 175 1·01 (0·53, 1·95) 0·93 (0·46, 1·85)
Oesophagogastric
junction
Type 1 2* 261 1·09 (0·75, 1·58) 1·02 (0·67, 1·56)
Type 2 2* 228 1·04 (0·70, 1·55) 0·80 (0·51, 1·26)
Tumour category
T0–2 1 335 1·36 (0·95, 1·94) 1·38 (0·91, 2·09)
T3–4 1 329 1·04 (0·79, 1·36) 0·95 (0·71, 1·27)
T0–2 2† 335 1·16 (0·78, 1·72) 1·28 (0·81, 2·01)
T3–4 2† 329 1·08 (0·80, 1·46) 0·95 (0·69, 1·31)
Node category
N0 1 315 1·01 (0·67, 1·51) 1·29 (0·80, 2·07)
N1 1 145 1·22 (0·81, 1·84) 1·09 (0·69, 1·73)
N2 1 120 1·38 (0·88, 2·17) 1·27 (0·78, 2·06)
N3 1 84 1·70 (1·02, 2·84) 1·42 (0·84, 2·39)
N0 2† 315 1·03 (0·66, 1·61) 1·43 (0·86, 2·37)
N1 2† 145 0·79 (0·49, 1·28) 0·80 (0·46, 1·38)
N2 2† 120 1·15 (0·69, 1·91) 0·87 (0·50, 1·53)
N3 2† 84 2·21 (1·25, 3·91) 1·59 (0·90, 2·79)
Values in parentheses are 95 per cent conﬁdence intervals. Model 1,
crude data; model 2, adjusted for *age, tumour category, tumour grade,
chemotherapy response and lymphovascular invasion, and †age, tumour
grade, chemotherapy response and lymphovascular invasion.
nodes and an R0 resection rate of 80·3 per cent, both of
which were statistically higher than values in the THO
group (P< 0·001). This did not translate into a signiﬁcant
difference in survival (HR 0·83, 95 per cent c.i. 0·60 to 1·14)
or time to recurrence (HR 0·90, 0·64 to 1·28) (Table 2).
No signiﬁcant differences in survival or recurrence were
encountered in subgroup analyses of more speciﬁc tumour
location, T or N category, except for the N3 subgroup
where there was a signiﬁcant beneﬁt for THO (Table 3).
Discussion
This study revealed no difference in overall survival or
time to tumour recurrence between THO and TTO after
adjustment for relevant confounding factors. Subgroup
analysis did not demonstrate any particular characteristics
that would select patients for extended resection (TTO).
In-hospital mortality and hospital stay were reduced
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after THO, but only the difference in hospital stay was
statistically signiﬁcant.
Some methodological issues deserve attention. In
contrast to the majority of other published studies, this
study assessed surgical approach within the context of
perioperative chemotherapy in patients deemed suitable for
multimodality treatment. However, it was not conducted
as a randomized trial, reﬂected by some differences
between the two groups, including stage at presentation
and the proportion of patients receiving neoadjuvant
chemotherapy. Although these features were taken into
consideration in the multivariable analysis, this does not
eliminate other sources of bias. It was not possible to
eliminate variations in practice and case mix between the
two units, or standardization regarding surgical technique,
a problem encountered even in randomized trials that
have examined radicality in upper gastrointestinal cancer
surgery11,12. This was offset by the fact that only three
surgeons performed or supervised all of the operations, that
management principles were similar between the units, and
there were no differences in outcomes.
The similarity in overall survival and tumour recurrence
between THO and TTO in the present study might
be taken to reﬂect the biology of oesophageal cancers
with their propensity for systemic dissemination negating
the potential beneﬁts of more radical surgery. It
may also reﬂect the pattern of node involvement for
adenocarcinomas of the oesophagus or oesophagogastric
junction, which is most commonly to the perigastric and
lower mediastinal lymph nodes13, areas that are dealt
with equally by both approaches. Wider lymph node
involvementmight then be viewed as equivalent to systemic
disease, unlikely to be inﬂuenced by a speciﬁc surgical
approach. Systemic chemotherapy may also nullify some
of the potential advantages of radical surgery by reducing
positive CRM rates and effectively treating lymph node
micrometastases14,15.
Few randomized clinical trials have directly addressed
the question of whether surgical approach affects
outcome1,2. Themost recent trial2, which excluded patients
receiving neoadjuvant therapy, showed lower morbidity
following THO, but no signiﬁcant difference in overall
survival. Subgroup analysis suggested a role for more rad-
ical surgery in patients with a low lymph node burden (1
to 8 lymph nodes involved) and in those with oesophageal
as opposed to junctional cancers2. The trial was, however,
underpowered to assess these features. The relevance of a
surgery-alone trial in the context of modern multimodality
treatment regimens is debatable.
Three further small randomized trials, three meta-
analyses and other large series have failed to demonstrate
any signiﬁcant survival advantage for more radical
surgery16–23. The question of whether TTO results in
greater morbidity is also debatable, particularly as compli-
cations are often poorly deﬁned24. The Dutch randomized
trial1 suggested higher rates of respiratory complications
after TTO, as did two of the meta-analyses21,23 and a
large population-based study from the USA16, although
other studies18,19,22 found no differences, and particular
complications, such as anastomotic stricture and recurrent
laryngeal nerve injury, seem more common after THO21.
Although some studies9,25,26 have suggested a survival
beneﬁt with increased lymph node yield, this was not
supported by the present study. Recommendations for
adequacy of lymphadenectomy according to tumour T
category9 may have some merit, particularly in mitigating
against the stage migration effect27,28. For the patient who
is truly node-negative there is unlikely to be survival beneﬁt
from the extensive removal of normal lymphatic tissue, and
for those with a high burden of lymph node involvement,
who are likely to have systemic disease, surgical radicality
is unlikely to extend survival greatly29.
Two challenging groups are patients with micrometas-
tases and those with a low volume of lymph node involve-
ment. Whether a proportion of these patients might be
cured or have a lower risk of local recurrence with more
radical lymphatic dissection remains controversial. The
present results suggest that this is not the case. Subgroup
analysis showed no beneﬁt for TTO in patients with N0
status, a group for which as many as 34 per cent might
have evidence of lymph node micrometastases30. Similarly,
there was no beneﬁt to radical surgery in the N1 subgroup,
in contrast to the results of the randomized trial2. Most
patients relapse with systemic metastases, regardless of the
surgical approach.
Tumour involvement of the CRM is widely accepted as
an important prognostic marker27,28. Rates of involvement
in the present study were similar to those reported after
neoadjuvant chemotherapy31,32, using the deﬁnition of
tumour cells 1mm or less from the margin as indicating
positivity. Overall rates of CRM involvement were similar
between surgical approaches. The more advanced tumours
were encountered in the TTO group, suggesting that
radical TTO may reduce the likelihood of margin
involvement, particularly in patients with T3–4 tumours.
Although it is accepted that THO cannot offer the same
access to the mediastinum and is, by deﬁnition, less radical
than TTO, there is little evidence of standardization in
the volume of perioesophageal tissue and diaphragmatic
crural resection removed by two-stage procedures33. In
theory, this lack of standardization is a confounder that
undermines studies assessing surgical radicality.
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As most patients in the West have distal oesophageal
or junctional tumours, this local surgery can be performed
equally well with both procedures; the only real difference
is the extent of mediastinal lymphadenectomy and the
opportunity to obtain a clear CRM for long bulky tumours
with TTO. The present study implies that the number
of patients who might beneﬁt from adoption of the latter
approach is small and may well be offset by survival after
THO in those unﬁt for TTO.
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A B S T R A C T
Purpose
Neoadjuvant chemotherapy is established in the management of most resectable esophageal and
esophagogastric junction adenocarcinomas. However, assessing the downstaging effects of
chemotherapy and predicting response to treatment remain challenging, and the relative impor-
tance of tumor stage before and after chemotherapy is debatable.
Methods
We analyzed consecutive resections for esophageal or esophagogastric junction adenocarcinomas
performed at two high-volume cancer centers in London between 2000 and 2010. After standard
investigations and multidisciplinary team consensus, all patients were allocated a clinical tumor
stage before treatment, which was compared with pathologic stage after surgical resection.
Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis.
Results
Among 584 included patients, 400 patients (68%) received neoadjuvant chemotherapy. Patients with
downstaged tumors after neoadjuvant chemotherapy experienced improved survival compared with
patients without response (P .001), and such downstaging (hazard ratio, 0.43; 95% CI, 0.31 to 0.59) was
the strongest independent predictor of survival after adjusting for patient age, tumor grade, clinical tumor
stage, lymphovascular invasion, resection margin status, and surgical resection type. Patients downstaged
by chemotherapy, compared with patients with no response, experienced lower rates of local recurrence
(6% v 13%, respectively; P  .030) and systemic recurrence (19% v 29%, respectively; P  .027) and
improved Mandard tumor regression scores (P  .001). Survival was strongly dictated by stage after
neoadjuvant chemotherapy, rather than clinical stage at presentation.
Conclusion
The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvant chemo-
therapy determines prognosis rather than the clinical stage before neoadjuvant chemotherapy,
indicating the importance of focusing on postchemotherapy staging to more accurately predict
outcome and eligibility for surgery. Patients who are downstaged by neoadjuvant chemotherapy
benefit from reduced rates of local and systemic recurrence.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Preoperative chemotherapy has become established
in the treatment of most patients with resectable
esophageal cancer in the United Kingdom after a
survival benefit was demonstrated in large random-
ized controlled trials.1-3 The potential benefits of
preoperative chemotherapy include downstaging of
the primary tumor, facilitating complete surgical re-
section, and treating systemic micrometastases.4,5 If
one adopts the philosophy that a high proportion of
newly diagnosed esophageal cancers have occult
metastatic disease at initial presentation, it follows
that systemically delivered therapy might be a criti-
cal factor in altering the long-term prognosis when
combined with surgery.
However, the absolute benefit of neoadju-
vant chemotherapy remains relatively low. In
two of the more contemporaneous trials, the
absolute improvement in survival was less than
15%, and therefore, most patients did not benefit
from optimal chemotherapy.1,3 Identification of
these patients would represent significant clinical
progress and could potentially herald patient-
specific management.
The aim of this study was to assess the long-
term outcomes of an unselected population of pa-
tients undergoing preoperative chemotherapy for
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esophageal adenocarcinoma. Our primary hypothesis was that the
tumor stage after neoadjuvant chemotherapy would determine sur-
vival rather than the tumor stage at presentation. We also aimed to
assess to what extent patients with esophageal or esophagogastric
junctionadenocarcinomawhoaredownstagedbyneoadjuvantchem-




A prospectively collected database between the years 2000 and 2010
consisting of 680 consecutive resections for esophageal or esophagogastric
junction (Siewert type I or II6) tumors was used. The database represents a
collaboration between two high-volume institutions for esophageal cancer
in London, United Kingdom (St Thomas’ Hospital and Royal Mars-
den Hospital).
Among the 96 patients excluded from this cohort were 15 patients who
underwent surgery for benign disease, one patient without histology, and 80
patients with squamous cell carcinoma of the esophagus. Therefore, the final
study cohort consisted of 584 patients with adenocarcinoma of the esophagus
or esophagogastric junction. Of these, 400 patients (68%) underwent preop-
erative chemotherapy, whereas the remaining 184 patients (32%) underwent
surgery alone.
Tumor Staging
All patients were discussed in a specialist upper GI multidisciplinary
team meeting and underwent a standard protocol of investigation that in-
cluded endoscopy, computed tomography (CT), endoscopic ultrasound
(EUS), and latterly fluorodeoxyglucosepositron emission tomography (FDG-
PET). Each patient was allocated a tumor stage (cTNM) before commence-
ment of neoadjuvant chemotherapy as decided by themultidisciplinary team.
After neoadjuvant chemotherapy, patients were restaged using CT (thorax,
abdomen, and pelvis), but not routinely using endoscopy, EUS, or fluorode-
oxyglucose PET. All patients underwent definitive resection and, therefore,
hadfinal tumorhistologyavailable for comparison (ypTNM), andanalyzedby
a member of a team of dedicated upper GI histopathologists. This pathologic
stage was determined using the seventh edition of the American Joint Com-
mittee onCancer TNMstaging system.7 Downstagingwas defined as a reduc-
tion in T stage or N stage of pathologic staging (ypTNM) compared with
clinical staging (cTNM). Pathologic tumor regression used a categorical scale
between 1 (complete pathologic response) and 5 (no response) as originally
described byMandard.8
Clinical Management
During the study period from January 1, 2000, to December 31, 2010,
chemotherapy practice in the United Kingdom evolved rapidly. After the
successful completion of a large multicenter randomized trial,2 two cycles of
preoperative cisplatin and fluorouracil became the standard treatment of
resectable esophageal cancer. A second United Kingdom–based randomized
trial was published in 2006, inwhich patients received three cycles of preoper-
ative epirubicin, cisplatin, and fluorouracil (ECF), followed by three cycles of
the same regimen postoperatively.1 In 2008, the final results of a further
randomized trial were published in which fluorouracil was safely replaced by
the oral fluoropyrimidine capecitabine, and hence, epirubicin, cisplatin, and
capecitabine largely replaced ECF.9
Thresholds for chemotherapywere also loweredover the 10-year period,
initially including all patients staged as having T3 tumors or involved lymph
nodes. Later (since 2005), patients staged at T2N0 were also considered for
neoadjuvant chemotherapy. This group of patients from the initial period of
studywho did notmeet the criteria for neoadjuvant therapy and patients who
were not administered chemotherapy for medical reasons or personal choice
were used as a control group. It was never the intention of the this study to
specifically compare chemotherapy regimens, but rather to analyze the overall
effects of neoadjuvant chemotherapy on outcomes. The surgical approach
consisted of transhiatal or transthoracic esophagectomy, primarily dictated by
individual surgeon preference.
Statistical Analysis
Descriptive statistics were used to present demographics and oncologic
outcomes. Survival analysis was performed using the Kaplan-Meier method
and log-rank test, and P .05 was used to determine statistical significance.
Survival was calculated from the date of surgery. The Fisher’s exact test and2
test were used to assess categorical variables, whereas the t test and Mann-
Whitney U test were used to analyze continuous variables.
Cox proportional hazards models were used to calculate hazard ratios
(HRs) with 95% CIs for the association between tumor downstaging (study
exposure) and the twomain study outcomes, overall anddisease-free survival.
Crude (model 1) and adjusted (model 2) analyses were performed. The prog-
nostic markers adjusted for in the multivariable model included patient age
(continuous), clinical tumor stage (T1/2N0, T1/2N, T3/4N0, or T3/4N),
tumor grade (well, moderately, or poorly differentiated), lymphovascular in-
vasion (yes or no), resection margin status (R0 or R1), and surgical resection
type (transhiatal or transthoracic esophagectomy). Pathologic tumor stage
andMandard tumor regression scores were excluded from themodel because
theseparameters also reflect tumor response to chemotherapyandwouldhave
confounded themodel. To evaluate the proportional hazards assumption, the
correlationwas calculated between Schoenfeld residuals for the covariates and
the ranking of individual treatment failure times. Furthermore, we also used a
graphical approach to compare log-log survival curves. The proportional
hazards assumptionwasmet.Datamanagement and analyseswere performed
usingSASversion9.4 software (SAS Institute,Cary,NC). Ethical (institutional
review board) approval was granted for use of the database.
RESULTS
Patient Characteristics
Ofthe584patients included, themeanagewas63years (range,28
to 83 years), with a majority of patients being men (86%). Demo-
graphics and stagingdataof the studyparticipants are listed inTable 1.
In-hospitalmortalitywas 2.5%, and themedian lengthof hospital stay
was 15 days. Overall survival of the cohort was 80% and 45% at 1 and
5 years, respectively.
Surgery consisted of transhiatal (n  232) and transthoracic
(n 353) esophagectomy. Three surgeons performed or supervised
all of the operations, and there were no differences in mortality or
survival according to individual surgeon or unit performing the sur-
gery. Overall R0 resection rate was 60%, using the Royal College of
Pathologists criteria of a positive margin (ie, tumor at or within 1
mm of the circumferential resection margin).10 This was equiva-
lent to an 87% R0 resection rate using the American College of
Pathologists definition.7 Median lymph node yields in the down-
staged and nondownstaged groups were 19 and 18 lymph nodes,
respectively (P .7741)
The predominant chemotherapy regimens included cisplatin
and fluorouracil (n 57), ECF (n 218), and epirubicin, cisplatin,
andcapecitabine (n112),whichaccounted for387 (96%)of the400
patients who underwent neoadjuvant chemotherapy. Themajority of
patients (n380;95%)wereadministered two, three,or fourcyclesof
neoadjuvant treatment. The chemotherapy regimen did not signifi-
cantly affect the likelihood of tumor downstaging (P .6665)
Downstaging Effect of Chemotherapy
In the group receiving neoadjuvant chemotherapy, 175 patients
(44%)benefitted fromadownstagingeffect.Thisgroupof responders,
compared with nonresponders, had improved rates of clear surgical
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Table 1. Demographics and Clinical Characteristics According to Neoadjuvant Chemotherapy Administration in Patients Undergoing Surgery for
Esophageal Adenocarcinoma
Characteristic
No Chemotherapy Chemotherapy (downstaged)
Chemotherapy
(not downstaged)
PNo. of Patients % No. of Patients % No. of Patients %
Total patients 184 31.5 175 30.0 225 38.5
Age, years .7735
Mean 64 62 61
SD 9 10 9
Range 34-83 28-81 33-78
Sex .1545
Male 159 86.4 155 88.6 188 83.6
Female 25 13.6 20 11.4 37 16.4
Tumor location .2397
Esophageal 49 26.6 25 14.3 22 9.8
Type I EGJ 79 42.9 72 41.1 108 48.0
Type II EGJ 56 30.4 78 44.6 95 42.2
Histology  .001
Adenocarcinoma 156 84.8 148 84.6 225 100.0
HGD 28 15.2 0 0.0 0 0.0
CPR 0 0.0 27 15.4 0 0.0
Tumor stage (clinical)  .001
T0N0 33 17.9 0 0.0 0 0.0
T1-2N0 85 46.2 4 2.3 7 3.1
T1-2N1-3 11 6.0 11 6.3 28 12.4
T3-4N0 22 12.0 18 10.3 50 22.2
T3-4N1-3 33 17.9 142 81.1 140 62.2
Tumor stage (pathologic)  .001
T0N0 28 15.2 27 15.4 0 0.0
T1-2N0 70 38.0 59 33.7 5 2.2
T1-2N1-3 34 18.5 51 29.1 28 12.4
T3-4N0 16 8.7 36 20.6 25 11.1
T3-4N1-3 36 19.6 2 1.1 167 74.2
Tumor grade (differentiation) .0138
HGD 28 15.2 0 0.0 0 0.0
Well 18 9.8 9 5.1 2 0.9
Moderate 94 51.1 101 57.7 120 53.3
Poor 44 23.9 65 37.1 103 45.8
Surgical resection .0323
Transhiatal 118 64.1 59 33.7 54 24.0
Transthoracic 66 35.9 116 66.3 171 76.0
Lymph node yield, No. .7741†
Median 15 19 18
Q1-Q3 9-20 12-28 12-29
Range 0-61 4-73 0-75
Chemotherapy regimen .6665
CF — — 29 16.6 28 12.4
ECF — — 94 53.7 124 55.1
ECX — — 46 26.3 66 29.3
Other — — 6 3.4 7 3.1
Chemotherapy response  .001
Complete — — 27 15.4 0 0.0
Good — — 12 6.9 3 1.3
Moderate — — 64 36.6 53 23.6
Poor — — 41 23.4 103 45.8
No response — — 18 10.3 35 15.6
Unknown response — — 13 7.4 31 13.8
Lymphovascular invasion  .001
Negative 117 63.6 132 75.4 70 31.1
Positive 67 36.4 43 24.6 155 68.9
(continued on following page)
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resectionmargins (R0: 74% v 40%, respectively; P .001) and lower
rates of isolated local recurrence (6% v 13%, respectively; P  .03).
The responders also experienced lower rates of systemic metastatic
recurrence compared with nonresponders, both alone (19% v 29%,
respectively; P .027) and in combination with locoregional recur-
rence (30% v 48%, respectively; P .001). The majority of down-
staged patients had evidence of pathologic response to neoadjuvant
chemotherapy (Mandard tumor regression score of 1 to 4 in 144 of
162 patients; 89%). This group of downstaged patients had signifi-
cantly improved Mandard tumor regression scores compared with
patients who were not downstaged (P .001).
In patients undergoing primary surgery, clinical staging was ac-
curate in 78% of patients (correctly staged, n  144 [78%]; under-
staged, n  30 [16%]; overstaged, n  11 [6%]). However,
postchemotherapy staging didnot discriminate betweenpatientswho
achieved a response to chemotherapy and those who did not (CT
showing response to chemotherapy: downstaged, 59%; not down-
staged, 61%; P .86).
Survival Analysis
Themultivariable adjusted Cox regression analysis revealed that
tumor downstaging (HR, 0.49; 95%CI, 0.35 to 0.68), lymphovascular
invasion (HR, 1.88; 95%CI, 1.39 to 2.55), and positive (R1) resection
margin (HR, 1.69; 95%CI, 1.27 to 2.25)were independentmarkers of
overall and disease-specific survival, whereas patient age (HR, 1.01;
95% CI ,0.99 to 1.03) and surgical resection type (HR, 1.11; 95% CI,
0.83 to 1.49) were not (Table 2). In patients staged as cT3/4N who
benefitted from a downstaging effect from chemotherapy, the 5-year
survivalwas significantly improved comparedwith the corresponding
nondownstaged group (52.5% v 12.6%, respectively; P  .001; Ap-
pendix Fig A1, online only).
Figures 1 to 4 represent a more detailed survival analysis of the
patients initially staged at cT3/4Nwho proceeded to chemother-
apy and were downstaged to ypT0N0 (Fig 1), ypT1/2N– (Fig 2),
ypT1/2N (Fig 3), or ypT3/4N– (Fig 4). In each survival graph, the
two control curves represent stage-matched patients who were not
administered neoadjuvant chemotherapy (pTNM) and patients
who were not downstaged by chemotherapy (ie, the nonre-
sponders who were still ypT3/4N after surgical resection). In all
of these survival analyses, a significant survival benefit was seen in
the chemotherapy responders versus nonresponders (P  .001),
and there was no difference observed between the responders and
stage-matched controls.
DISCUSSION
This study indicates that the established local downstaging effect of
neoadjuvant chemotherapy in resectable esophageal adenocarci-
noma is also associated with a reduced systemic relapse rate and an
overall improvement in survival that is independent of other
known prognostic factors. Patients who had downstaging of their
primary tumor after chemotherapy had survival comparable to
that of patients with equivalent early-stage tumors who did not
require chemotherapy. Thus, tumor stage after neoadjuvant chem-
otherapy seems to be more important than initial stage at presen-
tation in terms of assessing prognosis.
Somemethodologic issues deserve attention. This study allowed
for the long-term follow-up of a large cohort of patients undergoing
neoadjuvant chemotherapy and surgery for esophageal cancer. To the
best of our knowledge, noprevious studyhas been able to quantify the
local and systemic downstaging effects of systemic therapy in this
Table 1. Demographics and Clinical Characteristics According to Neoadjuvant Chemotherapy Administration in Patients Undergoing Surgery for
Esophageal Adenocarcinoma (continued)
Characteristic
No Chemotherapy Chemotherapy (downstaged)
Chemotherapy
(not downstaged)
PNo. of Patients % No. of Patients % No. of Patients %
Margin status  .001
R0 127 69.0 130 74.3 91 40.4
R1 57 31.0 45 25.7 134 59.6
Recurrence during follow-up  .001
No recurrence 133 72.3 111 63.4 88 39.1
Locoregional 17 9.2 11 6.3 30 13.3
Metastases 21 11.4 34 19.4 66 29.3
Both 13 7.1 19 10.9 41 18.2
In-hospital death .7622‡
No 179 97.3 171 97.7 218 96.9
Yes 5 2.7 4 2.3 7 3.1
Hospital stay, days .7343†
Median 15 16 16
Q1-Q3 12-22 12-24 13-23
Range 7-78 7-101 7-191
NOTE. P value refers to 2 comparison of chemotherapy (downstaged) versus chemotherapy (not downstaged).
Abbreviations: CF, cisplatin and fluorouracil; CPR, complete pathological response; ECF, epirubicin, cisplatin, and fluorouracil; ECX, epirubicin, cisplatin, and
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manner and combine it with robust long-term follow-up data. How-
ever, this trial was not designed as a randomized trial, and therefore,
despite being adjusted for several potential confounding factors, it is
susceptible tobias.Althoughtwocenters contributeddata, stagingand
management principles were similar, and there were no differences in
outcomes according to individual surgeonorunit of presentation.We
elected toanalyzepatientswithadenocarcinomaexclusively, to adhere
to the principle of treating these tumors as distinct pathologic entities
from squamous carcinomas. Failure to do somight introduce bias, an
issue that has been raised in randomized controlled trials where a
discrepancy in the effects of treatment has been documented between
esophageal tumor subtypes.11 Although our study contains a combi-
nationof transhiatal andtransthoracic resections, surgical approach in
our own data set had no impact on overall survival or disease recur-
rence when adjusted for relevant confounding factors.12
The clinical relevance of our study is that it shows that pathologic
stage after chemotherapy strongly dictates prognosis, whereas the
initial pretreatment staging does this only to a limited extent. This
indicates that advanced diagnostic staging procedures (eg, PET-CT,
EUS, or magnetic resonance imaging) should be used after neoadju-
vant chemotherapy. The major clinical decision making should be
based on this staging rather than the initial staging. Themain purpose
of the initial staging would be to identify any distant metastases (thus
precluding curatively intended treatment) and to provide a baseline
fromwhich to compare response to treatment. This would be a novel
clinical approach that might improve clinical decision making and
survival after curatively intended treatment.
One criticism of the this study is the use of pathologic stage as a
surrogate for postchemotherapy stage. Clearly, the use of imaging
modalities to predict stage after chemotherapy would best inform
prospective management. However, this study was intended as proof
of concept, to identify the mechanism of benefit after chemotherapy
Table 2. Crude and Adjusted Analysis Analyzing the Impact on Tumor
Downstaging After Neoadjuvant Chemotherapy in Patients Undergoing













Yes 0.49 0.35 to 0.68 0.50 0.35 to 0.71
Patient age 1.01 0.99 to 1.03 0.99 0.98 to 1.01
Clinical stage (cTNM)
cT1/2N Ref Ref
cT1/2N 1.64 0.66 to 4.09 1.51 0.50 to 4.58
cT3/4N– 0.81 0.47 to 1.39 0.94 0.50 to 1.77
cT3/4 N 1.40 0.89 to 2.19 1.70 0.99 to 2.90
Tumor grade (differentiation)
Moderate Ref Ref
Well 0.68 0.21 to 2.19 1.13 0.41 to 3.14
Poor 0.88 0.67 to 1.14 0.87 0.65 to 1.17
Lymphovascular invasion
No Ref Ref
Yes 1.88 1.39 to 2.55 1.75 1.27 to 2.42
Resection margin
R0 Ref Ref
R1 1.69 1.27 to 2.25 1.84 1.35 to 2.51
Surgical resection
Transhiatal Ref Ref
Transthoracic 1.11 0.83 to 1.49 1.10 0.80 to 1.51
NOTE. Model 1  crude. Model 2  adjusted for age, tumor stage (cTNM),
tumor grade, lymphovascular invasion, resection margin status (R0/R1), and
surgical resection type.
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Fig 1. Comparison of surgically treated patients with esophageal adenocarcinoma,
downstaged from cT3/4N to ypT0N0. Control groups are represented by
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Fig 2. Comparison of surgically treated patients with esophageal adenocarcinoma,
downstaged from cT3/4N to ypT1/2N–. Control groups are represented by
cT3/4N to ypT3/4N (not downstaged) and T1/2N– (no chemotherapy).
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andattempt toquantify suchbenefit inapracticalway. Indoing so, the
use of final pathologic stage to define responders is inherently more
accurate. We have been able to show that a patient presenting with a
T3N2 tumor who is downstaged to a T1N0 tumor has equivalent
survival to a patient who was T1N0 from the outset. This simple
philosophy has practical value as we aim to select patients for surgery
but is fundamentally reliant on our ability to accurately stage patients
before and after chemotherapy.
We have attempted to address the two alternative explanations
for our study’s finding that tumor downstaging is of critical impor-
tance to the outcome of these patients. The first is that the patients
labeled as downstaged were simply overstaged at presentation. Al-
though this may conceivably account for a small proportion of the
benefit seen in our study, the literature would suggest that staging
investigations have a tendency to understage disease rather than over-
stage it, a trendborneoutbyour control groupofpatients undergoing
surgery alone. These patients were accurately staged in 78% of cases
and overstaged in only 6% of cases. Given the magnitude of benefit
seen with chemotherapy downstaging, it is difficult to comprehend
that such infrequent overstaging could significantly impact on the
overall results of our study. Furthermore, the fact thatourdownstaged
patients experienced significantly improved Mandard tumor regres-
sion scores suggests validity in the selection of this group. Finally, the
argument that the downstaged patients could represent a cohort with
favorable tumor biology ismitigated by the fact that tumordownstag-
ing was the most significant independent prognostic factor in the
multivariable model that adjusted for these features.
The finding that a patient’s survival might be determined by his
or her stage after neoadjuvant chemotherapy lends strength to the
argument that patients who respond to chemotherapy can still be
successfully considered for radical treatment, regardless of the initial
locoregional stage of disease. However, patients who did not respond
to chemotherapy actually experienced worse survival than patients of
equivalent stage who underwent primary surgery. It is logical that
persisting with ineffective chemotherapy in this scenario serves no
benefit, while adding to the overall morbidity of treatment.
These results highlight thepotential importanceof tailoring ther-
apy to the individual patient. Such algorithms could include pro-
longed systemic therapy in patients who are responding well to
treatment, intensifyingneoadjuvant treatments (eg, adding radiother-
apy to chemotherapy) in those with locally unfavorable tumors (eg,
threatened surgicalmargins), ordiverting carefully selectedpatients to
early surgery in the absence of a response to induction therapy. Some
patients who continue to have poor prognostic features after chemo-
therapymay not benefit from surgery at all. A prerequisite for adopt-
ing this tailored approach is the ability to measure response to
neoadjuvant chemotherapy accurately. Unfortunately, there are no
validatedpredictivemolecularmarkers for response tochemotherapy.
Pathologic tumor regressionmaybe associatedwith improvements in
survival,8 but this is not commonly used to inform pre- or postoper-
ative decision making regarding therapy. CT imaging is notoriously
inaccurate atmeasuring response to chemotherapy, and although the
addition of PET and EUS may improve restaging accuracy, these
limitations currently preclude individualized therapy.13
The benefits of neoadjuvant chemotherapy in terms of local
downstaging have been previously documented.4 Our results concur
with this, showing that a significant proportion of patients achieve a
reduction in stage, which translates into improved survival, improved
surgical resection rates, and reduced locoregional recurrence.
What is considerably more debatable is whether and to what
extent chemotherapy has an additional systemic effect.5 If the answer
to this question is no, then it would seem logical to treat all patients
with chemoradiotherapy because this would result in higher rates of
pathologic response andcomplete resectionof theprimary tumor and
surrounding lymphatics.11,14 However, there are concerns that the
lower radiosensitizing dose of systemic chemotherapy that such treat-
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Fig 3. Comparison of surgically treated patients with esophageal adenocarcinoma,
downstaged from cT3/4N to ypT1/2N. Control groups are represented by














365 730 1,095 1,460 2,1901,825 2,555 2,920 3,285 3,650
Start T3/4 N+ end T3/4 N+
Start T3/4 N+ end T3/4 N-
T3/4 N- no chemotherapy
No. at risk
T3/4 N+ not 
downstaged
T3/4 N+ to 
T3/4 N-




















Fig 4. Comparison of surgically treated patients with esophageal adenocarcinoma,
downstaged from cT3/4N to ypT3/4N–. Control groups are represented by
cT3/4N to ypT3/4N (not downstaged) and T3/4N– (no chemotherapy).
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effects. Moreover, the evidence for underlying systemic micrometas-
tases at the time of surgery for esophageal cancer is compelling.15 The
overwhelmingmajority of patients, including even those with a com-
plete pathologic response after chemoradiotherapy, still die of meta-
static disease.16-18A significant proportionof patientswithN0 tumors
will have evidence of lymph node micrometastases when additional
pathologic analysis is performed, exceeding 30% in some studies.19-22
Bone marrow aspirates have also shown that up to 60% of patients
undergoing esophageal cancer surgery have malignant cells in the
circulation.15,23 In the absence of a systemic effect of treatment, all of
these patients would presumably die of their disease.
The benefits of neoadjuvant chemotherapy for responding pa-
tients in our study are convincing, with a 57% reduction in the risk of
cancer recurrence and death demonstrated for the 44% of patients
who were downstaged. This benefit is significantly greater than the
relative risk reduction demonstrated in the relevant clinical trials,1-3
which take into account both responders and nonresponders. Nota-
bly, the benefits of systemic chemotherapy are not limited to down-
staging;wealsodemonstrate a concurrent reduction in theoccurrence
of systemic metastatic disease for responding patients, providing
sound evidence for the elimination ofmicrometastases.We have pre-
viously reported that pathologic stage (after chemotherapy) and
pathologic tumor response (Mandard tumor regression score) are
independently prognostic after esophagectomy.17 If chemotherapy
only served to downstage the primary tumor, then these two param-
eters could not bemutually exclusive, and all of the benefit of chemo-
therapy would be represented by the reduced stage of disease after
chemotherapy. Therefore, we believe that the benefits of downstaging
are independent of, and complimentary to, pathologic tumor regres-
sion. Given the high rates of systemic recurrence in these patients and
the convincing reduction in both local and systemic relapse demon-
strated in our study with neoadjuvant chemotherapy, we believe that
this is an appropriate treatment for such patients.
In conclusion, this study indicates that tumor stage after neo-
adjuvant chemotherapy determines survival in patients with ade-
nocarcinoma of the esophagus and esophagogastric junction. The
importance of tumor downstaging in terms of survival, complete
surgical resection, and recurrence pattern has significant clinical
implications. Thedemonstrationof a systemic effect of chemother-
apy is particularly poignant at a timewhenmuch controversy exists
regarding the optimal neoadjuvant treatment strategy for these
cancers. Improving the assessment of response to neoadjuvant
chemotherapy is critical if we are to successfully adopt a policy of
individualized therapy.
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Fig A1. Survival of surgically treated patients with esophageal adenocarcinoma clinically staged (cTNM) as T3/4N according to administration of chemotherapy and
the downstaging effect of treatment.
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7. Supplementary studies 
  
Whilst the above three studies, go some way to improving our understanding of the 
staging, natural history and treatment of oesophageal adenocarcinoma, in some 
respects they pose even more questions. All three emphasise, to a greater or lesser 
extent, the importance of improved staging after chemotherapy and the implications of 
being able to predict those patients who are not responding to neo-adjuvant 
chemotherapy. However, these parameters have proven to be particularly challenging 
despite being the subject of extensive investigation.  
 
In an attempt to answer some of the questions highlighted by these studies, this 
chapter briefly presents the results of on-going studies that focus on three key areas :- 
 
1. Validation of the ERD model proposed in study 1 
2. Prediction of circumferential margin involvement – A CT based model  
3. Applications of CT following NAC – the accuracy of staging, and prediction of 




7.1 Early recurrence and death after oesophagectomy : 
validation of a survival model 
 
Study 1 identified locally advanced tumours (T3/4) with three or more involved lymph 
nodes (N2 or N3), poor differentiation, positive resection margins and poor response to 
chemotherapy as independent risk factors for ERD (early recurrence and death within 
one year of surgery). A subsequent cohort of 70 patients operated for oesophageal 
cancer between 2011 and 2013 i.e. in the two years following completion of study 1 
was evaluated. At the time of census all patients were at least 1 year from surgery. 
Again, the primary outcome was early recurrence and death within 12 months of 
surgery.  
 
Of the 70 patients included, 45 were alive with no signs of recurrence and 5 deceased 
with no recurrence at the time of death. 13 patients suffered a recurrence and died of 
their disease (8 of whom recurred and died within 12 months of surgery). A further 7 
patients were alive at the time of census, with documented tumour recurrence. 
 
8 patients (8/70; 11.5%) suffered ERD. Of these, 6 patients (75%) had systemic 
metastases.  7 (87.5%) had T3 tumours, all 8 (100%) were lymph node positive (4 N1; 
4 N2/3), 7 (87.5%) had R1 resections, 6 (75%) had poorly differentiated tumours and 7 
(87.5%) were Mandard 4 or 5 on pathological tumour regression assessment (the other 
patient had no chemotherapy).  
 
Of the remaining patients, those with confirmed recurrence within 18 months of surgery 
(n=8) also displayed many of the same adverse prognostic characteristics. 
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The combination of a T3/4 N2/3, poorly differentiated tumour, R1 resection and 
Mandard score of 4 or 5 led to an 80% chance of recurrence and death within 12 
months of surgery. Encouragingly, the proportion of patients suffering ERD has fallen 
from 17% to 12%, which may reflect improvements in staging. Advanced stage 
(particularly T3/4-N2/3), poor differentiation, positive resection margins and poor 
chemotherapy response (Mandard 4 or 5) continue to predict poor outcome, supporting 
the model previously described. In combination, these characteristics resulted in an 
unacceptably high probability of dying within 1 year of surgery.  
 
The presence of these adverse prognostic markers should prompt a change in 
strategy, as these patients will never recover from surgery before succumbing to their 
disease. However, prediction of this group requires an accurate assessment of tumour 
stage following NAC and an ability to predict patients at risk of an R1 resection as well 







7.2 CRM prediction model 
 
I acknowledge the contribution of Dr. Connie Yip, who is the joint author of this, as yet 
unpublished, study. Dr. Audrey Jacques and Prof. Vicky Goh (Consultant GI 
radiologists, Guy’s & St Thomas’ NHS foundation trust) analysed the CT images for 
this study. 
 
Predicting patients who will have CRM involvement at surgery has significant clinical 
applications. These patients have a poor prognosis and are at increased risk of local 
and systemic recurrence. Not only does an R1 resection feature in the model predicting 
early recurrence and death (study 1), but these patients may benefit from tailored 
strategies to minimise the risk of positive margins. Such strategies could include the 
use of neo-adjuvant CRT in certain cases and the selection of these patients for 
transthoracic resection, based in part on the results presented in this thesis. This study 
aimed to define and validate a predictive model for CRM involvement, based on 
contrast enhanced CT. 
 
133 patients who underwent CT prior to surgery were studied. These post neo-adjuvant 
chemotherapy CT scans were reviewed by two independent radiologists and relevant 
radiological parameters extracted. Univariate and multivariable logistic regressions 
were performed. A logistic regression (LR) model and a simplified CRMscore3 model 
were constructed using parameters with clinical and statistical significance: invasion of 
adjacent structures, circumferential aortic contact >90°, pleural thickening (IAP); 
longest trans-axial tumour dimension (LD) and node positivity (N+). Model performance 
was assessed using area under the curve (AUC) in the development (n=68) and 
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validation cohort (n=65). The CRMscore3 performed as well as the LR model. Being more 
readily applicable to clinical practice it was evaluated for its ability to predict CRM. 
 
In the development cohort the sensitivity, specificity, positive predictive value and 
negative predictive value of the CRMscore3 was 22%, 98%, 86% and 66% respectively 
for those patients scoring 3.The CRMscore3 model performed less well when applied to a 
separate validation cohort; however, it still had potential in identifying a group of 
patients with a very high risk of positive CRM. 
 
A limitation of this model is its lack of sensitivity. The majority of patients who might 
benefit from intensification of neo-adjuvant therapy would not be identified with a score 
of 3. Lowering the threshold score to 2 reduces the specificity such that up to half of the 
patients would perhaps be over-treated. Clearly, more accurate prediction of CRM 
status would further enable a philosophy of treatment intensification for those at high 
risk of CRM positivity. Whether such escalation of treatment would improve outcomes 
in these patients remains debatable and would require a prospective trial. 
 
Another potential criticism is the use of post-chemotherapy CT evaluation. It might be 
argued that the initial staging CT should be used to assess CRM risk, with neo-
adjuvant treatment tailored accordingly. However, given that systemic chemotherapy 
has been shown to reduce CRM involvement, and the clear importance of systemic 
therapy demonstrated in study 3, it would be inconsistent to then suggest these 
patients be considered for NACRT from the outset. Whilst they may be at increased 
risk of local recurrence by virtue of a positive CRM, they are also at a much higher risk 
of systemic disease. Hence the logic in treating with systemic therapy in the first 
instance and selecting those for escalation based on post chemotherapy CRM status. 
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Thus only patients who are likely to gain a local benefit from CRT are recommended for 
this treatment and none are disadvantaged by sub-optimal systemic therapy. In 
suggesting this algorithm, it is accepted that there is currently no prospective evidence 
in favour of this approach, which would be a pre-requisite to implementing such a 
strategy. 
 
In summary, this study constructed and validated a simple CT-based CRM predictive 
model which could be used to identify patients at risk of a positive CRM in standard 
clinical practice. The model incorporates a combination of three radiological 
parameters which are easily identified on routine CT assessment. Although it has the 
potential to impact on clinical decision making, further refinements are needed to 
improve the accuracy of the model to the extent that it could be prospectively studied 
as a decision making tool. 
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7.3 The accuracy and application of CT imaging following neo-
adjuvant chemotherapy for oesophageal cancer 
 
Stage after chemotherapy is important prognostically, yet in the UK, minimal resources 
are allocated to the assessment of tumours following neo-adjuvant treatment. In most 
units, CT alone is used to re-stage oesophageal cancers, despite numerous studies 
suggesting this modality is inaccurate at doing so. 
 
This study evaluated the use of CT staging after neo-adjuvant chemotherapy to assess 
the accuracy of CT staging after NAC, and the ability of CT to predict the adverse 
prognostic parameters identified in study 1 (namely T3/4, N2/3, R1 resection, Mandard 
tumour regression score of 4 or 5/5). The study cohort included 93 patients with 
adenocarcinomas of the oesophagus and complete staging data. 
 
This study confirmed that re-staging after NAC with CT is often inaccurate. It is well 
known that CT struggles to predict T stage, particularly after chemotherapy, where the 
presence of fibrosis makes this interpretation difficult. In the allocation of T stage to 
clinically prognostic sub-groups i.e. T1-2 or T3-4, CT was accurate in 51 (55%) 
patients, understaged in 18 (19%) and overstaged in 24 (26%). Therefore for the 
prediction of T3/4 status the sensitivity, specificity, PPV and NPV of CT were 63%, 
47%, 56% and 54% respectively. 
  
TNM 7 mandates an assessment of the number of involved lymph nodes to assess “N” 
status. Whilst CT is reasonably accurate at making an overall assessment of whether a 
patient is node positive or node negative, its ability to specify the number of involved 
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lymph nodes is poor. This results in high rates of over-staging (26%) and under-staging 
(41%) of nodal status. When CT stages N2/3 disease it has a high positive predictive 
value, but a very low sensitivity such that only 14% of N2/3 patients would be identified. 
The implications of this for a model predicting ERD are that CT alone would only pick 
up a small proportion of patients at risk, but within that group, would do so with high 
levels of confidence. Ultimately, the poor sensitivity of CT supports the need for more 
staging information after NAC.  
 
Encouragingly, this preliminary data support a role for CT in the assessment of 
response to chemotherapy. This information is important for two reasons; firstly a poor 
response may predict patients at high risk of ERD. Secondly, response to 
chemotherapy (or lack of) may in future be used to guide further treatment strategies. 
An assessment on CT of whether there has been a down-staging effect from 
chemotherapy (e.g. RECIST score) combined with a quantitative estimation of this 
response (% volume change) has shown significant promise, particularly at 
distinguishing Mandard 1-3 from Mandard 4-5 tumour regression grades (sensitivity, 
specificity, PPV and NPV of 79%, 62%, 76% and 66%). This is of interest, as it 
corresponds to the prognostic cut-offs identified by the ERD model in study 1 and other 
studies [47].  It also has the potential to identify the “down-staged” group, highlighted in 
study 3 as having a significantly improved prognosis.  
 
Given that PET has also been shown to predict response to chemotherapy with 
reasonable accuracy, it would be interesting to combine the model above with a 
measure of biological response such as SUV reduction or tumour heterogeneity.  It is 
conceivable that the combination of these modalities might improve accuracy further, to 
the point of being a clinically useful predictive tool for chemotherapy response 
assessment. 
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A logical extension of this was to evaluate whether the same parameters that predict 
response to chemotherapy might also predict margin status, this being the final variable 
required for a poor outcome (ERD) model. Whilst the lack of down-staging on CT (i.e. 
stable disease) and a tumour volume change of less than 50% did show some ability to 
identify those at risk of margin involvement, it lacked sufficient PPV to direct patient 
management. However, it may have potential if combined with other parameters, such 
as those identified in the CRMscore3 model described above. As such, a fourth point 
awarded for a lack of response to chemotherapy could improve the overall 
performance of the model (CRMscore4), making it more suitable for prospective clinical 
evaluation. 
 
In conclusion, CT staging after NAC is inaccurate. This modality, in isolation, is unable 
to provide sufficient staging detail to inform prospective decision-making, implying that 
further staging investigations should be considered after NAC, such as PET, EUS or 
MRI.  
 
However, there may be a role for CT in predicting response to chemotherapy. Stable 
disease is a frequently used, yet misleading term, which implies status quo following 
chemotherapy is an encouraging outcome. On the contrary, “stable disease” by 
definition, means no appreciable improvement in the tumour, the connotations of which 
are entirely different when interpreting the perceived benefits of treatment. It is 
therefore not surprising that such patients are frequently found to have poor or no 
response to chemotherapy on pathological analysis. Stable disease combined with 
tumour volume change, may be able to predict chemotherapy response prior to 
surgery. Whilst CRM prediction remains challenging, the combination of the two 
predictive models described above may herald a clinically useful tool, one which merits 




8.1 Summary of findings  
 
The main findings of these studies are summarised below :- 
• Most patients (82%) suffering early recurrence and death (ERD) following 
surgery for AC of the oesophagus, do so with systemic metastases. 
• Prognostic features that independently predict ERD include pathological tumour 
stage (particularly T3/4 N2/3), poor tumour differentiation, R1 resection and 
poor response to neo-adjuvant chemotherapy (Mandard 4 or 5/5) 
• The combination of these factors has the potential to select a group of patients 
with a sufficiently poor outcome, that alternative strategies to surgery should be 
considered. A patient who remains T3/4 N2/3 after NAC, with an R1 resection, 
poorly differentiated tumour and poor response to NAC has a 15% chance of 
surviving 18 months from surgery. This model has been validated in a 
subsequent cohort of patients. 
• Limitations in the ability to accurately re-stage tumours after NAC and predict 
response to treatment, currently preclude the selection of this high risk group for 
alternative management strategies, and indeed any individually tailored therapy. 
CT in isolation is inadequate at TNM re-staging after chemotherapy. 
• Models predicting CRM involvement may be achievable, thus enhancing our 
ability to identify this poor prognostic factor prior to surgery, and potentially 
facilitating a change in neo-adjuvant treatment strategy in selected patients.  
• The more radical transthoracic surgery does not confer a survival benefit over 
the less radical transhiatal resection. Disease free survival and patterns of 
recurrence were also similar between operative approaches. 
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• Transhiatal resection resulted in a significantly reduced hospital stay and a 
trend towards reduced mortality compared to transthoracic oesophagectomy. 
These characteristics may make it particularly suitable for elderly patients or 
those with co-morbidities who are high risk for surgery. 
• Radical transthoracic resection did increase lymph node yields and R0 
resection rates, the latter most pronounced in T3/4 tumours, compared to 
transhiatal resection. Whilst this did not lead to improved survival, it suggests 
that small sub-groups may be selected for this approach.  
• Tumour stage after NAC, as opposed to initial stage at presentation, strongly 
determines survival for AC of the oesophagus. 
• Patients down-staged by NAC had significantly improved overall survival, 
improved R0 resection rates and reduced systemic relapse, supporting the role 
for NAC in both local down-staging and the elimination of micro-metastases. 
Down-staging was the strongest independent predictor of survival on 
multivariable analysis. 
• The ability to accurately predict down-staging after NAC would represent 
significant progress and may change patient management. Resources should 
focus on the assessment of tumour stage after chemotherapy. In the first 
instance this supports the use of PET/CT before and after chemotherapy, 
however other modalities such as EUS and MRI may have a future role to play. 
• The absence of a response to NAC on CT (i.e. stable disease), combined with a 
quantitative assessment of tumour volume change on chemotherapy has shown 






These studies have demonstrated the significant improvements in outcomes that can 
be achieved with a multi-disciplinary approach combined with modern investigation and 
treatment pathways. An in-hospital mortality rate of 2% aligned with an overall 5 year 
survival of 45% after oesophagectomy compares favourably to most published series [3, 
206].  
 
Early recurrence and death after oesophageal surgery is associated with certain 
adverse prognostic factors (advanced stage [T3/4 N2/3], poor differentiation, R1 
resection, poor/no response to chemotherapy [Mandard 4/5]), the combination of which 
leads to a very poor outcome. These patients have an unacceptably high risk of early 
recurrence after surgery and should be considered for alternative oncological 
treatments. 
 
Surgical approach does not seem to impact greatly on overall survival or the likelihood 
of recurrence. Whilst the more radical TTO may facilitate a greater lymphadenectomy 
and improve R0 resection rates in certain sub-groups, this did not translate into an  
overall survival advantage. There was  a trend towards lower mortality following THO 
and a significantly reduced hospital stay that could be taken as a surrogate for reduced 
morbidity.  
 
Stage after chemotherapy appears to be a more accurate predictor of outcome than 
initial tumour stage at presentation. Given its prognostic importance, the current 
allocation of resources to staging after chemotherapy is inadequate. In contrast, 
multiple investigations are used for initial tumour staging, some of which will not alter 
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decision-making and may be unnecessary. NAC has demonstrated ability to down-
stage the primary tumour and reduce the rates of systemic recurrence, therefore 
supporting its role in the elimination of micro-metastases in at least some cases.  
 
Taken together, these studies strongly support the philosophy of treating most 
potentially resectable oesophageal adenocarcinomas as a systemic disease. On the 
basis of the available evidence, neo-adjuvant chemotherapy followed by surgery 
should remain the mainstay of treatment for the majority of oesophageal 
adenocarcinomas, pending results from on-going RCTs. Predictive models that could 
directly guide individualised patient management are achievable but require improved 
staging after NAC. These could include selecting patients for specific neo-adjuvant 
treatment strategies, directing surgical approach in patients deemed suitable for 
resection and the avoidance of surgery in those who are unlikely to benefit.  
 
Some methodological issues deserve attention. These studies utilised a large 
prospectively collected database of oesophageal cancer patients, rigorously cross-
referenced with other available data sources to ensure accuracy. The high volume of 
patients, availability of long-term follow up and the use of a population that reflected 
real time working practice were all strengths of the database. The conclusions drawn 
from the analysis of this robust dataset are therefore of greater validity. However, none 
of the studies were conducted as randomised trials and hence, despite adjustments for 
known prognostic factors, were susceptible to bias from confounding. Whilst it was 
impossible to completely eliminate variations in practice between the two contributing 
units, management principles and overall outcomes were very similar between the 
institutions. Only three surgeons performed or supervised the surgeries, providing a 
consistency of surgical technique often lacking in multi-centre trials where this has 
been difficult to standardise. This thesis focussed on adenocarcinoma of the 
oesophagus and OGJ, given the extensive evidence that these tumours should be 
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treated as distinct pathological entities from squamous cell carcinomas. This added to 
the validity of our results by reducing the heterogeneity of the cohort.  
 
All of the studies used definitive pathological stage to stratify patients after surgery. 
Whilst this may be considered the gold standard in terms of analysing the true stage of 
the tumour, this information is not available at the time of patient selection for surgery. 
Clearly, the ability to improve prospective decision making is reliant on staging 
modalities accurately predicting tumour stage after NAC. The use of clinical staging 
after NAC in statistical models, would have allowed for assessment of the accuracy of 
such modalities. However, given that staging accuracy after NAC was not the primary 
clinical question, this (notoriously inaccurate) stage could have acted as another 
confounder, and was therefore avoided.  
 
The advantage of presenting a thesis by publication route is the acknowledgement, 
through peer review, of current clinical relevance in the field of oesophageal cancer 
surgery. Each of the three studies used a novel approach to add a new perspective to 
the existing literature. No study has specifically examined ERD in western patients with 
adenocarcinoma with a view to identifying factors that should lead to the avoidance of 
surgery. Whilst surgical resection type has been extensively studied, our patient 
numbers allowed for statistical models that examined surgical radicality in greater detail 
than previously performed. Additionally, this was investigated in the context of most 
patients undergoing peri-operative chemotherapy, whereas previous studies assessed 
patients undergoing surgery alone. Finally, no published study has been able to 
quantify the down-staging effects of NAC in a comparable way to that performed in 
study 3. The idea that a tumour behaves according to its stage after chemotherapy has 
practical value, as well as important implications for staging algorithms. With the 
confirmation of a systemic benefit following neo-adjuvant chemotherapy, and the 
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demonstration of AC as a predominantly systemic disease, it may be reasonably 
concluded that this is the correct strategy for most patients.  
 
In assessing the implications and clinical relevance of the results presented in this 
thesis, it would be logical to approach each step in the investigation and treatment 




8.2.1 Initial Staging  
The role of initial staging is predominantly to identify patients with metastatic disease 
who are not eligible for curative treatment, and to select the remainder for appropriate 
therapy. A curatively intended approach may include endoscopic resection or primary 
surgery for the earliest tumours (HGD or T1) or neo-adjuvant therapy followed by 
surgery in most other scenarios. This broadening of the indications for neo-adjuvant 
therapy over the last ten years in some ways simplifies the decision making 
requirements of initial staging. In patients proceeding to NAC, initial staging also needs 
to provide an adequate baseline from which to compare response to treatment.  
 
Currently most patients undergo a CT at diagnosis followed by EUS and PET, with 
additional laparoscopy performed for junctional tumours. Given the improvements in 
PET imaging and the ability to combine this with contrast enhanced CT (i.e. PET/CT), 
the need for separate CT and PET investigations will probably diminish in the future. 
The anatomical and physiological correlation afforded by PET/CT may actually provide 
sufficient local staging information to make most initial decisions, and thus EUS may 
become redundant in most patients. Notable exceptions to this may be the selection of 
early tumours for endoscopic therapy or locally advanced tumours, which may be 
rendered unresectable by tumour invasion of surrounding structures. EUS could be 
performed on a selective basis in these patients. The withdrawal of EUS from the 
standard investigation algorithm would place more demands on the reporting of 
PET/CT, particularly in the evaluation of nodal status, in order to comply with the 
requirements of TNM 7. It remains to be seen whether PET/CT can provide 
comparable accuracy to EUS in this specific setting. 
 
The literature would also suggest that PET/CT is accurate in the detection of 
metastases. Given that the justification for additional laparoscopy was based on 
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historical data that utilised CT alone, laparoscopy may nowadays be unnecessary in 
most patients with oesophageal or OGJ AC. 
 
With the demonstration that tumour stage after chemotherapy is the major determinant 
of survival, more important prognostically than initial tumour stage at presentation, it 
may be that the only staging investigation required in the majority of patients at 
diagnosis is a dedicated contrast enhanced PET/CT. This would allow for direct 
comparison with the same modality after NAC. The only reason to add further 
investigations at initial staging would be the finding that such modalities were useful at 
re-staging, and hence the desire to compare like for like, before and after 




8.2.2 Neo-adjuvant treatment 
The results of the CROSS study, a large randomised clinical trial from the Netherlands, 
have strengthened the argument for the use of NACRT in patients with lower 
oesophageal SCC. This subject was beyond the remit of this thesis which has focussed 
on adenocarcinoma of the oesophagus rather than squamous cell carcinoma [127]. 
 
In this same trial, however, the benefit of NACRT in adenocarcinoma did not reach 
statistical significance against a surgery alone control arm. There was also no benefit 
for NACRT in the sub-group of patients with lymph node positive disease. Hence, the 
criticism of this trial was that the lower radio-sensitizing dose of chemotherapy did not 
show any survival benefit in the two groups of patients with the greatest chance of 
systemic disease, i.e. those with adenocarcinoma and positive lymph nodes. 
Extrapolating from studies of definitive CRT, this discrepancy between AC and SCC is 
consistent, with the former being less responsive to radiotherapy [28, 230].  
 
A further study detailing the recurrence patterns of patients enrolled in the CROSS trial 
demonstrated the main benefit of NACRT to be a reduction in local recurrence (34% vs 
14%; p<0.001), particularly evident in SCC patients, with a more marginal reduction in 
systemic metastases compared to the surgery alone group (35% vs 29%; p=0.03) [243]. 
Other studies have failed to show any systemic benefit for NACRT [244]. Given the 
higher rates of systemic disease with AC, and the high incidence of metastases in 
patients following NACRT, a logical conclusion is that such treatment does not have 
adequate systemic efficacy despite its excellent local control statistics. 
 
To some extent, a similar criticism could be levelled at currently available 
chemotherapy regimens, as patients still die predominantly of systemic disease despite 
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systemic therapy. However, given the significant systemic benefit for NAC 
demonstrated in RCTs, supported by this thesis, and the additional morbidity of 
radiation, it would seem logical to treat adenocarcinoma patients with maximal 
systemic therapy in the first instance. This is based on the supposition that additional 
chemotherapy agents or higher doses of drugs made available by the omission of XRT, 
will have improved efficacy for micro-metastases, an issue that may be resolved by the 
results of on-going randomised trials. 
 
Whether a small proportion of patients at particular risk of isolated local recurrence may 
be selected for intensification of neo-adjuvant treatment, i.e. the addition of 
radiotherapy, is unclear from the literature, as it is not possible to predict these patients 
prior to surgery. Logically, they are the only group who might benefit from radiation as 
the remainder of patients’ prognoses are determined by the presence or absence of 
metastatic disease. Only 7% of patients in our series died with isolated local recurrence 
after oesophageal cancer surgery. The CROSS trial also demonstrated isolated local 
recurrence to be extremely rare, occurring in only 9% of patients after surgery 
compared to 3% after NACRT [243]. It therefore remains difficult to justify treating 
virtually all patients with XRT in order to conceivably benefit only a small minority. 
 
The use of a surrogate for high risk of local recurrence, such as a predictive model for 
circumferential margin (CRM) involvement (R1 resection), has shown some promise in 
our data. As the model is based on post-chemotherapy CT, patients would receive 
systemic therapy initially with the perceived systemic benefit of such treatment and the 
possibility of local down-staging. However, those still at high risk of a positive CRM 
could be escalated to CRT in an attempt to improve local control prior to resection. 
Whilst this strategy may be logical, it is important to note that 70% of patients with an 
R1 resection in our series still died of metastatic disease, not local recurrence. Indeed, 
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a similar pattern has been shown in other studies examining patients with a positive 
longitudinal margin who might have been expected to suffer local recurrence but 
actually died of systemic disease [40]. These patients tend to have advanced tumours 
with poor biology.  
 
Some studies have specifically looked at the intensification of neo-adjuvant treatment 
on an individual patient basis. The MUNICON II trial used PET to select “non-
responders” to NAC (less than 35% reduction in SUV) for additional XRT [130]. Whilst 
the metabolic responders had clearly improved outcomes, this trial demonstrated no 
survival benefit for additional XRT and high rates of systemic relapse regardless of the 
treatment regimen. The fact that survival was similar between the non-responding 
groups of patients in MUNICON (non-responders diverted to surgery) and MUNICON II 
(non-responders diverted to NACRT then surgery) using identical criteria, implies that it 
is the response to chemotherapy that ultimately dictates outcome in these patients. 
Non-responders to chemotherapy have a poor outcome irrespective of the choice of 
salvage strategy. Whether different criteria for the selection of patients for NACRT, as 
proposed by the CRM model, would affect this overall outcome remains uncertain. 
 
Compared to the use of “non-responders”, a predicted positive CRM may be a more 
logical indication for XRT as the treatment directly addresses the problem at hand i.e. 
an increased risk of local recurrence. The risk-benefit for additional radiation is clearly 
much improved in this specific group of patients than it would be in an unselected 
population. Whilst this algorithm would require prospective evaluation prior to 
implementation, it would seem intuitive given the relatively small number of patients 
who may conceivably benefit from such escalation, and the morbidity associated with 
radiotherapy. Clearly, it is also reliant on the accurate prediction of CRM status. 
Regardless of the criteria used to select neo-adjuvant treatment, the search for more 
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effective systemic therapy should remain paramount, as this will have a far greater 
impact on overall outcome than any measure targeting local control. 
 
In patients who are responding to chemotherapy, there is a strong argument for 
completing all six cycles of treatment prior to surgery. This would allow for maximal 
down-staging of the primary tumour, improved surgical margin rates and the 
guaranteed delivery of systemic therapy. Given that half of patients in the relevant 
RCTs did not complete chemotherapy following surgery, and the clear demonstration 
that adenocarcinoma of the oesophagus recurs systemically, the rationale for maximal 
up-front chemotherapy is strong. The impact of prolonged chemotherapy on 
complication rates following surgery would have to be examined prospectively.  
 
A major challenge is what to do with the non-responders to NAC, assuming this group 
can be confidently identified. Our data confirms that these patients do poorly after 
surgery, gaining no survival benefit whilst suffering the side-effects of treatment. It is 
tempting, therefore, to change strategy in the absence of a response to chemotherapy. 
Diverting to surgery is one option, however these patients have a high risk of systemic 
relapse and will have been subjected to major resection with little realistic chance of 
cure. Likewise, escalating to NACRT may improve local response rates, but most 
patients will relapse systemically and prospective trial evidence (MUNICON II) confirms 
no benefit to this approach. One alternative might be second-line systemic therapy, 
which could include chemotherapeutic or biological agents, with surgery being reserved 
only for responders to such treatment. However, no such option currently exists with 
any reasonable evidence base. Finally, it could be that diverting non-responding 
patients away from the surgical pathway altogether, towards definitive chemo-radiation 
represents the most pragmatic compromise, and one that may offer comparable 
survival to surgery anyway in this particular group. One challenge with this approach, 
112
for AC at least, is that the lower response rates of these tumours to CRT guarantees 
that a proportion of these patients will subsequently return to the MDT meeting with 
residual or recurrent cancer, and an oncologist wishing to explore the options for 
salvage surgery. Whilst this may seem unappealing given the initial prognosis, those 
patients with poor biology would likely have been selected out by this approach due to 
the development of metastatic disease during oncological treatment. The remainder, 
could simply be observed on the basis that they have had their definitive treatment or, 
in selected cases, may be considered for salvage resection after a reasonable period 
of surveillance.  
 
A pre-requisite for implementing such major changes to these treatment pathways is 
the ability to identify which patients are not responding to chemotherapy. Nowhere is 
this principle more important than in the prediction of those patients unlikely to survive 
12 months from surgery. They tend to have the ominous combination of advanced 
tumours and minimal response to chemotherapy. As a result of being inappropriately 
selected for resection, they have not benefitted from surgery. However, it still remains 
difficult to advise a fit patient with a technically resectable tumour not to have surgery 
on the basis of a predicted outcome. As such, the incidence of ERD will never be zero, 




8.2.3 Re-staging after chemotherapy  
The assessment of response to NAC continues to represent a significant challenge. 
Current practice utilises multiple staging investigations at initial presentation but only 
CT assessment after NAC. As most studies have demonstrated this modality to be 
poor at re-staging, and given the clear importance of stage after NAC on survival, there 
remains a conspicuous discrepancy in the allocation of imaging resources to this 
critical point in the algorithm [72]. A minimum requirement would appear to be the use of 
contrast enhanced PET/CT before and after chemotherapy. As well as being the most 
sensitive investigation for metastatic disease, PET/CT allows for TNM re-staging 
combined with a measure of physiological response to treatment [245]. Newer 
parameters measurable by PET, such as MTV, TLG and tumour heterogeneity are only 
likely to improve this response assessment in the future.  
 
There may also be some merit in comparing chemotherapy response within lymph 
nodes to that in the primary tumour, as there is some evidence that such response may 
not be proportional [50]. Although a down-staging response in regional lymph nodes may 
be more difficult to detect radiologically, it is arguably more important prognostically 
than a reduction in the size of the primary tumour. However, the evidence suggests 
that both sub-groups will have improved survival compared to patients exhibiting no 
response whatsoever [50]. Either way, it is clear that radiologists need to be challenged 
to be as specific as possible in their reporting of tumour stage after chemotherapy, and 
this should be prospectively documented as part of institutional and national dataset 
requirements. 
 
Numerous studies have examined the role of EUS after NACRT for response 
prediction, with conflicting results. Whilst assessing T stage after chemotherapy is 
difficult with EUS, its role in the evaluation of nodal status following NAC is promising. 
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EUS with FNA has been successfully used to identify residual nodal disease after CRT 
(sensitivity 82%, accuracy 68%) [158]. Given that on-going N2 or N3 disease after NAC 
has been shown to be the strongest predictor of ERD following surgery in study 1, this 
could be used to justify a role for repeat EUS in high risk patients. A patient with 
confirmed multi-node disease after NAC is unlikely to benefit from surgery due to the 
high probability of occult metastatic disease. Two challenges in adopting this approach 
are the false positive results created by traversing the primary tumour to sample lymph 
nodes, and the need to sample multiple nodes in order to prove N2 or N3 disease. 
  
The role of MRI in anatomical re-staging and response assessment following 
chemotherapy is unknown but has significant potential. On-going prospective studies 
will decide whether MRI is to be used as a niche investigation or whether it will become 
a mainstream staging modality that supersedes CT and potentially even PET in the 
future.  
 
MRI has also shown promise in its ability to predict CRM status, akin to its role in rectal 
cancer [246, 247]. An R1 resection was a negative prognostic indicator in all three studies. 
A means of predicting CRM involvement could be important in the context of data from 
this thesis, and might influence decision-making in several ways :- 
1. An R1 resection would be one component of a predictive model for early 
recurrence and death 
2. A patient at risk of an R1 resection could be selected for intensification of neo-
adjuvant therapy 
3. A patient with an oesophageal tumour and threatened surgical margins could 
be selected for a transthoracic approach on the basis of an improved rate of 
margin clearance with this strategy. 
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As such, further work to improve CRM predictive modelling is justified.  
 
Although susceptible to some degree of placebo effect, a patients’ symptomatic 
response to chemotherapy remains an important clinical marker that should not be 
ignored. An improvement in swallowing, and weight gain on chemotherapy are markers 
of response that are arguably as sensitive as any currently available imaging modality 




8.2.4 Tailored therapy 
In patients who have received NAC, tumour stage after chemotherapy will dictate their 
prognosis. Patients who benefit from a down-staging effect from chemotherapy will 
have lower rates of R1 resection, reduced likelihood of metastatic recurrence and 
improved overall survival. However, patients who do not respond to NAC will have 
gained no benefit from treatment, yet still suffered the morbidity of chemotherapy.  
 
Currently, patients who are resectable after 3 cycles of NAC proceed to surgery, with 
the majority requiring 3 further cycles of adjuvant treatment assuming they are able to 
tolerate such treatment. A number of scenarios exist following neo-adjuvant 
chemotherapy that merit consideration:- 
1. Radiological CPR – Most patients will continue to surgery on the basis that 
radiological assessment cannot guarantee complete eradication of all tumour 
cells. Assuming complete response could be predicted radiologically, the 
benefit of surgical resection in the context of a tumour with no residual viable 
cancer cells is contentious. The data on patients with CPR after NACRT would 
suggest that 50% still suffer recurrence within 5 years of surgery. Whilst most of 
these develop systemic metastases, the remainder could conceivably have 
been prevented by surgical resection, therefore justifying this operative 
approach. In contrast, our data suggest that a CPR following NAC, although 
less commonly encountered than after NACRT, is almost synonymous with 
cure, resulting in a 90% 5 year survival. A prospective trial would be required to 
determine whether these patients gain any benefit from surgery. In the 
meantime, pending improvements in the radiological assessment of CPR and 
convincing evidence to support a conservative approach in such patients, 
surgical resection should still be considered in this scenario. 
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2. Clear evidence of down-staging – These patients have benefitted from neo-
adjuvant treatment. Proceeding to surgery at this point is a very reasonable, 
evidence-based strategy. However, as outlined above, 40% of patients will not 
complete adjuvant therapy following surgery. This number is too high, for a sub-
group of patients who are actually benefitting from systemic treatment. The 
alternative is therefore to complete all 6 cycles of chemotherapy prior to 
surgery, thus maximising tumour down-staging and guaranteeing the delivery of 
beneficial systemic therapy. 
 
 
3. Disease progression to metastases – These cases unfortunately represent 
tumours with poor biology, such that these patients likely would have recurred 
early had they been treated with primary surgery. 
 
4. A resectable tumour but poor prognostic markers (either disease progression 
on chemotherapy or poor initial prognostic markers with no improvement on 
NAC) - These patients are at very high risk of ERD, which may in future be 
quantifiable with prognostic modelling. Surgery should be considered with 
caution as these patients may be better served by definitive CRT or second line 
systemic therapy. This decision must be taken on an individual patient basis 
following discussion of the risks and benefits of each option.  
 
 
5. “Stable disease” - Arguably the most challenging group. Whilst such a patient is 
not likely to have benefitted much from NAC, in the absence of a contra-
indication to surgery, they will probably continue to resection along the current 
pathway. This may be one of the few scenarios where initial staging is important 
in assessing prognosis, given that these tumours have not been down-staged 
by chemotherapy. In the context of advanced initial staging, “stable disease” on 
imaging is very unlikely to result in cure following surgery, in a similar way to 
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that described above in 4. However, for earlier tumours, a poor response to 
chemotherapy may be an indication for resection as there is no benefit in 
continuing with toxic systemic therapy, and a resected early stage tumour may 
still offer a reasonable long term prognosis. Assuming a poor response to 
chemotherapy is confirmed on pathological analysis, the merits of completing 
adjuvant chemotherapy are far from certain. This subject requires prospective 
evaluation in its own right. 
 
6. A bulky primary tumour, with no evidence of metastatic disease, but radiological 
features suggestive of a locally unfavourable tumour despite NAC (e.g. contact 
with diaphragmatic crura, pericardium or pleura). These patients have had 
systemic treatment but remain at high risk of an R1 resection following surgery. 
Some radiological evidence of response to initial chemotherapy may prompt a 
continuation of this treatment to six cycles i.e. primary chemotherapy. The 
group without a response to NAC, and predicted CRM involvement, could be 
individually selected for the addition of radiotherapy, with the intention of 
reducing this risk at surgery. A transthoracic resection may then be considered 
following this intensified neo-adjuvant treatment, to maximise the chance of 
achieving a negative margin, whilst accepting that systemic disease is still most 
likely to dictate outcome.  
 
7. Advanced disease at diagnosis e.g. nodal involvement categorised as “M1” 
disease – Patients with advanced nodal disease outside the surgical field (e.g. 
aorto-caval lymph nodes at diagnosis), may increasingly be put down a primary 
chemotherapy route only to re-present a therapeutic dilemma by virtue of an 
excellent response to treatment. This increasingly common scenario, often in 
young patients, is one in which there is radiological resolution of the disease 
that originally rendered the patient unresectable and hence the debate as to 
whether they should be treated according to their pre-chemotherapy (M1) or 
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post chemotherapy (M0) stage.  Undoubtedly, these patients require detailed 
re-staging to elicit their true post-chemotherapy stage, a process that is likely to 
include endoscopy, PET/CT and laparoscopy as a minimum. However, if we 
were to extrapolate from the results of study 3, basing treatment on the stage of 
disease after chemotherapy, there may theoretically be a role for resection in 
this carefully selected group. Clearly this would venture significantly away from 
a conventional treatment pathway and these patients would therefore have to 

















8.2.5 The choice of surgery  
This data, and the results of numerous trials, would suggest that the choice of 
operation does not have a significant bearing on long term survival [208, 248, 249]. Overall, 
more radical surgery does not confer a survival benefit compared to less radical 
surgery and may increase the morbidity and mortality [4, 213] . The reasons for this 
presumably relate to the natural history of oesophageal cancer. Most patients have 
advanced disease at presentation that is incurable by surgery alone. Those with early 
disease have a low probability of margin involvement and lymph node metastases and 
hence the extensive removal of normal lymphatic tissue is unlikely to greatly extend 
survival. In the remainder of patients, the lymphadenectomy in the abdomen and lower 
mediastinum afforded by THO is likely to provide comparable oncological clearance of 
the lymph nodes at greatest risk of involvement. Lymph node metastases outwith this 
field are almost certainly a manifestation of systemic disease such that radical surgery 
would not influence survival in these patients. 
   
However, some individual scenarios do merit consideration in light of the available 
data. An elderly or medically unfit patient, particularly with underlying respiratory 
disease, might reasonably be considered for THO given the equivalent overall survival 
and potentially reduced morbidity with this approach. This tailored strategy for 
transhiatal resection in high risk patients has been proposed elsewhere in the 
literature [250]. However, proponents of TTO might argue that the results of study 2 
hardly justify a change in approach. The outcomes from TTO in study 2 exceeded 
historical controls. A hospital mortality of 3% dating back to 2000, with a hospital stay 
of 17 days represent excellent short term outcomes over this period of time. Aligned 
with a 5 year survival approaching 50%, these results would be considered acceptable 
anywhere in the world.  
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One further group where a selective policy may be considered is that of a younger, fit 
patient with a T3/4 oesophageal tumour and N1 disease on clinical staging i.e. a low 
number of involved lymph nodes. In this dataset, a radical TTO reduced the chance of 
an R1 resection in T3/4 tumours and the HR for survival favoured TTO in the N1 sub-
group (albeit non-significantly). Given that the RCT also suggested that this limited 
node positive group may benefit from more radical surgery, this would be a reasonable 
strategy based on the currently available evidence. 
 
Given the demographic shift of oesophageal cancer from mid oesophageal SCC to 
adenocarcinoma of the lower oesophagus and OGJ, some surgeons believe there is an 
expanding role for the left thoraco-abdominal approach which affords excellent access 
to the hiatus, particularly for bulky junctional tumours in obese patients. Whilst there is 
no evidence to support the use of the left chest approach over the right chest, access 
to the tumour is excellent, making it a useful option in selected cases.  
 
Whilst MIO has been successfully implemented in a number of high volume institutions 
worldwide, it has not been uniformally accepted within UK practice, partly due to higher 
complication rates encountered on surgeons’ learning curves [251]. The same can be 
said of robotic surgery [252]. The results of these techniques must be robustly audited to 
ensure there is no compromise in standards, in pursuit of smaller scars. That said, the 
potential advantages of well delivered minimally invasive surgery are overtly apparent 
from the worldwide literature [219]. 
 
Ultimately, of the various available operative approaches to the oesophagus and OGJ, 
none have been consistently shown to improve survival. The pragmatic conclusion, 
therefore, is that surgeons familiar with one particular technique may justifiably 
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continue to do so without compromising patient outcomes. Whilst there may 
conceivably be a role for selecting certain patients for a specific operative approach, 




8.3 Future directions 
 
All of the steps highlighted above, mark a transition away from generic treatment 
pathways, towards patient specific therapy. As data become available to guide such 
decision making, this represents a logical progression, however it is more labour 
intensive requiring a greater attention to detail on behalf of clinicians and the multi-
disciplinary team as a whole. 
 
One of the intentions of the new 8th edition TNM staging system, to which this database 
has been invited to contribute, is the development of a prognostic scoring system 
based on the outcomes of over 10,000 patients worldwide. This has the potential to 
shape the management of oesophageal cancer patients, particularly those who are 
unlikely to benefit from surgery. Such prognostic characteristics will be available to 
input on web-based and phone applications in real time, providing an immediate 
estimate of prognosis in a clinic setting. Whilst this is likely to be more sophisticated 
than other available predictive scores such as the Nottingham prognostic index for 
breast cancer, such scoring systems have been met with scepticism in some quarters. 
Whilst there will always be scope for decision-making based on an individual patient’s 
wishes and a clinician’s intuition, such a guide would undoubtedly be useful, 
particularly in justifying a non-operative approach. 
 
Nowhere will individualised therapy become more prominent than in the field of 
oncology, where gene signatures and biological mapping of individual tumours will 
probably be commonplace in the future. Systemic therapy will target specific receptors 
using combinations of biological agents. The knowledge that a tumour expresses 
receptors for a given therapy will reduce the likelihood of a patients undergoing 
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systemic treatment for no benefit. Identifying patients who are not responding to 
treatment will still be critical as these patients may benefit from tumour re-profiling and 
second line therapy. Staging should incorporate anatomical and physiological 
assessments of the tumour both before and after chemotherapy, with best available 
evidence currently supporting the use of PET/CT. However MRI has shown some 
promise and has the potential to supersede CT in the future. 
 
Overall, the role of surgery is likely to diminish. Early tumours will be treated by 
endoscopic therapy provided the long term results of this treatment show equivalent 
outcomes to surgery. As predictive models improve, particularly the ability to select 
patients with very poor forecasted survival following surgery, this group will probably be 
offered alternative oncological therapies. With more patients receiving definitive CRT, 
there is likely to be an increased demand for salvage resection in those patients with 
residual or recurrent disease.  
 
The availability of tumour specific biological therapies will improve systemic treatment, 
such that only patients who have had prolonged and effective therapy will proceed to 
surgery. This may include patients who were initially deemed unsuitable for surgery, 
but become eligible courtesy of a good response to treatment. Whilst down-staging 
should prompt a re-evaluation of surgical options, prospective studies would need to 
verify the benefit of such an approach. The reduced morbidity and side-effect profile of 
biological agents, compared to chemotherapy, may allow for long term systemic 
treatment in a similar fashion to that employed for hormone receptor positive breast 
cancer or the use of Tyrosine Kinase inhibitors for gastro-intestinal stromal tumours. 
The morbidity and mortality associated with surgery, and the availability of alternative 
treatments, will inevitably drive further improvements in surgical standards and the 




In conclusion, this thesis has shown in a large cohort of oesophageal resections that 
significant advances are being made in the investigation and treatment of these 
cancers. Outcomes are improving such that 5 year survival from surgery now 
approaches 50%. Nonetheless, 20% of patients fail to survive one year from surgery, 
highlighting the need to predict early recurrence and death. Most patients require neo-
adjuvant therapy and current evidence supports the use of systemic chemotherapy as 
the first line treatment in patients with oesophageal adenocarcinoma. Arguably the two 
greatest challenges in this field are how to improve the efficacy of systemic therapy and 
the accurate measurement of tumour response to such treatment. The inevitable 
introduction of targeted therapies will change the landscape of oesophageal cancer 
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A.1 Study 1 protocol  
 
Early recurrence and death after oesophageal cancer surgery 
 
Background 
Early recurrence and death after surgery for oesophageal cancer is a devastating 
outcome in which the magnitude of the surgery has not been justified by the duration of 
survival. Quality of life studies have demonstrated that the restoration of physical and 
emotional well-being takes at least 12-18 months from surgery. Therefore, a patient 
who dies within a year of surgery will not have re-gained their pre-operative quality of 
life before succumbing to their disease. If these patients could be identified 
prospectively, they could be offered alternative oncological therapies.  
 
Aim 
To compare a group of patients suffering ERD with a group of long-term survivors (>3 
years from surgery) to identify the clinico-pathological characteristics associated with 
ERD.  
Lead author : AD 
Analysis / statistics : FM 
Target journal : BJS 
 
Methods 
Red = Database column for selected parameter 
Design: Cohort study based on the database of 680 patients (only those with 
malignant disease) – identified by Included in ERD study (Y) operated on at STH and 
RMH during the period 2000-2011 with follow-up until March 2012. Included are 
patients diagnosed with adenocarcinoma, adenosquamous and squamous cell 
carcinoma, and high grade dysplasia (HGD).  
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 Groups are identified by ERD (ERD = 0; LTS = 1). ERD is calculated as survival of less 
than one year from date of surgery AND Recurrence (=Yes) 
 
Main outcomes:  1. Odds ratio of presence in ERD group (rather than LTS) to 
identify factors associated with ERD 
 2. Patterns of recurrence 
 
Survival outcomes on database 
1. Patient is Dead or Alive (Dead (1) or Alive (0)) 
2. If dead, Date of death gives survival 
3. If Alive, Date last seen gives survival 
4. If dead with recurrence Outcome (Dead – distant mets, locoregional 




Multivariate model to include (Potential confounding factors): 
1. Age at operation - DOB (Date of birth) (categorical) 
2. Grade: HGD/CPR, Well, Moderate, or Poor 
3. Tumour stage TNM (7th Ed) 
 (6 groups) – T0-2 N0, T0-2 N1, T0-2 N2-3, T3-4 N0, T3-4 N1, T3-4 N2/3 
5. Chemotherapy response : Complete pathological response, Good OR partial 
response, Poor OR No response, Not applicable (i.e. no chemo given), not recorded 
(i.e. response unknown, chemo given)  
6. Lymphovascular invasion: Yes or no 
7. Resection type (R0/1/2): R0 (clear margins) vs R1/2 (R1 microscopic disease at 
margin OR R2 macroscopic disease)  
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8. Albumin (Albumin) <40, ≥40 
9. CRP (CRP) <5, ≥5 
 
Analysis (FM to do) 
1. Multivariable model (crude and adjusted analysis) of the above clinic-
pathological parameters to identify those associated with ERD. All patients and 
Adenocarcinoma sub-group (exclude SCC, adenosquamous) i.e. perform two runs of 
the model. 
 
Other data we would like to have for the manuscript  
1. Demographics 
2. Oncology data (stage of disease, % having chemo, R0/1/2, LVI, chemo response 
etc)  
3. In-hosp mortality – In hospital mortality (yes or no) 
4. Hospital stay – Hospital LOS (continuous) 
5. LN Yield – Total LNs (continuous)  
6. CRM involvement – Radial margin positive (where CRM + = Yes OR <1mm ; 
CRM - = No) 
7. Recurrence pattern – loco-regional, distant mets, locoregional AND distant 




1. Can ERD be predicted (? Predictive modelling) 
2. Comparison with Zhang study (SCC) 
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A.2 Study 2 protocol  
 
The effect of the radicality of surgery on survival in oesophageal cancer 
 
Background 
The optimal surgical approach to oesophageal cancer is controversial. Some advocate 
radical surgery with two (or even three) stage procedures. However there is very 
limited evidence to suggest that this benefits patients when compared to the transhiatal 
approach, which typically is a less radical operation with limited possibilities for lymph 
node dissection in the chest. An advantage of the Transhiatal approach is the lower 
risk of pulmonary complications. The primary RCT that has compared the two 
approaches, showed no statistically significant differences in terms of overall survival, 
but greater morbidity in the transthoracic (2-stage) group [Hulscher et al 2002]. On sub-
group analysis, there was a trend to long-term survival benefit in patients undergoing 2-
Stage (radical) surgery in those with a low volume of positive lymph nodes. 
 
Aim 
To compare Transhiatal and 2-Stage procedures performed at STH and RMH over a 
ten year period to establish if there is any benefit  to more radical surgery in terms of 
overall and disease free survival as primary outcomes.  
 
Target journal : BJS, Annals of surgery  
 
Methods 
Red = Database column for selected parameter 
Design: Cohort study based on the database of 665 patients (only those with 
malignant disease – I have identified these by Included in radicality study (Y) operated 
on at STH and RMH during the period 2000-2011 with follow-up until March 2012. 
Included are patients diagnosed with adenocarcinoma, adenosquamous and 
squamous cell carcinoma, and high grade dysplasia (HGD).  
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Exposures: We will compare Transhiatal (THO) to 2-Stage (2ST) procedures (THO or 
2ST) regarding survival. THO includes all patients operated on with this procedure. 
2ST includes the surgical procedures Ivor Lewis, Laparoscopic Ivor Lewis, MIO, and 
Left thoraco-abdominal (LTA). 
 
 
Main outcomes:  1. Overall mortality within 5 years of surgery (or within period of 
follow-up if less than 5 years) 
2. Disease-specific mortality (with documented tumour 
recurrence) within 5 years of surgery or period of follow-up if less 
than 5 years. 
3. Disease free survival   
 
 
Survival outcomes on database 
1. Patient is Dead or Alive (Dead (1) or Alive (0)) 
2. If dead, Date of death gives survival 
3. If Alive, Date last seen gives survival 
4. If dead with recurrence Outcome (Dead – distant mets, locoregional 






Multivariate model to include (Potential confounding factors): 
1. Age at operation - DOB (Date of birth) <60, 60-70, >70? (FM to decide cut-offs) 
2. Grade: HGD/CPR, Well, Moderate, or Poor 
3. Tumour stage TNM (7th Ed) 
 (6 groups) – Tis/HGD/T0, T1-2 N0, T1-2 N1-3, T3-4 N0, T3-4 N1, T3-4 N2/3 
5. Chemotherapy response : Complete pathological response, Good OR partial 
response, Poor OR No response, Not applicable (i.e. no chemo given), not recorded 
(i.e. response unknown, chemo given)  
6. Lymphovascular invasion: Yes or no 
7. Surgical approach (THO or 2ST) 
AND interchangeable with surgical approach (THO vs 2-ST) :- 
8. Resection type (R0/1/2): R0 (clear margins) vs R1/2 (R1 microscopic disease at 
margin OR R2 macroscopic disease)  
9. Lymph node yield (Total LNs) (0-9,10-19,20-29,>=30) 
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Analysis (FM to do) 
1. Overall mortality -  Include Surgical approach in a Cox regression multivariate 
model with other known prognostic factors to assess whether approach affects survival 
when these are taken into account. Possible confounders as above. 
LN yield & Margin status (R0 vs R1/2) to replace surgical approach in 2nd run of 
model (This may demonstrate which of the two proposed mechanisms of 
difference is the most important) 
 
2. Disease specific mortality – similar to above but using Recurrence Y/N (and date 
of recurrence rather than date of death) 
LN yield & Margin status (R0 vs R1/2) to replace surgical approach in 2nd run of 
model 
 
Other data we would like to have for the manuscript  
1. Demographics 
2. Oncology data (stage of disease, % having chemo, R0/1/2, LVI, chemo response 
etc)  
3. In-hosp mortality – (THO vs 2ST) In hospital mortality (yes or no) 
4. Hosp stay – comparison of means/medians (THO vs 2ST) Hospital LOS 
(continuous) 
5. LN Yield – comparison of means / medians Total LNs (continuous)  
6. CRM involvement –THO / 2ST vs CRM + / CRM – Radial margin positive (where 
CRM + = Yes OR <1mm ; CRM - = No) 
7. Recurrence pattern – THO / 2ST vs loco-regional, distant mets, locoregional 
AND distant mets  ? Recurrence 
8. Survival analysis stratified by T stage, N stage (N0-3), tumour location 




Additional proposal :- 
 
1. The world oes CA collaboration recently published guidelines for adequacy of 
lymphadenectomy based on T stage. I am interested to know if increased 
Lymph node yield in itself gives a prognostic advantage (they suggest it does).  
 
2. In terms of radicality I think you can argue that 2ST may provide two theoretical 
advantages 
 A. Greater Lymphadenectomy 
 B. Removal of peri-oesophageal tissue thus reducing your CRM (R1) rate 
 
That is why I felt we should look at these two features separately to see if surgical 
approach affects these.  It almost certainly will affect A….. B will be interesting 
 
I propose we run the Adjusted model twice :- 
 
(i). Age, stage, grade, Chemo response, Lymphovascular invasion, Surgical approach 
(THO vs 2-Stage) (ie EXCLUDE MARGIN STATUS and LN yield as this may be 
affected by surgical approach which is already in the model) 
(ii).  Age, stage, grade, Chemo response,  Lymphovascular invasion, Margin status, 
Lymph node Yield (ie take surgical approach OUT of model and replace it with Margin 
status and LN yield) 
 
2. We need to do further analysis by tumour location e.g. Oes/Type I/ Type II. There is 
some evidence that a THO may be as good as 2ST for Junctional tumours but not as 
effective for true oesophageal / Type 1. We should therefore stratify according to 
tumour location and tumour stage in a separate analysis. 
 
If we do the above we could reasonably draw conclusions on : 
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1. Whether 2-Stage resection confers an advantage over Transhiatal surgery in terms 
of overall survival, and disease free survival (Adjusted model) 
2. Whether a subset of patients may be better served by more radical surgery (as 
previously suggested in the RCT) (stratified analysis) (T1/2, T3/4, N0, N1, N2, N3, Oes, 
Type 1 OGJ, Type 2 OGJ) 
3. How the two approaches compare in terms of Hosp stay, In hospital mortality, LN 
yield, Margin status and Recurrence pattern (simple statistics) 
 
Ref 
Hulscher, J.B., et al., Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med, 2002. 
347(21): p. 1662-9. 
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A.3 Study 3 protocol
Tumour down-staging after neo-adjuvant chemotherapy determines survival in 
adenocarcinoma of the oesophagus and oesophago-gastric junction 
Introduction 
Neo-adjuvant chemotherapy has become established in the treatment of oesophageal 
cancer in the UK following a survival benefit demonstrated in three high profile 
randomised controlled trials (OEO-2, MAGIC, FFCD). However, the effects of down-
staging following chemotherapy are poorly understood and the ability to quantify this 
benefit remains elusive. 
The assumption that systemic chemotherapy may have the ability to eradicate micro-
metastases is one of the arguments for this strategy over and above neo-adjuvant 
chemo-radiation. Additionally, the relative importance of tumour stage before and after 
chemotherapy is unknown.  
Hypotheses 
1. Down-staging by neo-adjuvant chemotherapy results in a survival benefit
2. This survival benefit is manifest by improved local AND systemic control
3. Staging after chemotherapy is more important prognostically than initial staging
Target journals : Lancet Oncology, JCO 
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Statistical analysis (FM to do) 
1. Survival (KM) analysis examining stage before and after chemotherapy (T0N0, 
T1-2 N-, T1-2 N+, T3-4 N-, T3-4 N+) 
2. Compare down-staged patients and non-downstaged patients in terms of 
pathological response (Mandard score), Local recurrence and systemic 
recurrence 
3. Multivariate model, utilising Downstaged Y/N (study exposure), adjusted for 
known confounding factors (patient age, tumour grade, lympho-vascular 
invasion, clinical stage). Outcome measures – overall survival, disease free 
survival 
4. Correlation between Tumour Downstaged (Y/N) and Chemotherapy response 
i.e. Mandard scores (Complete/good/moderate/poor/no response).  
 
 
Database parameters for multivariable model (#3) 
Patients to be included in study :- Included in chemo study = Y 





Age at operation (continuous) 
Pre-op stage (T0N0; T1-2 N-; T1-2 N+; T3-4 N-; T3-4 N+)  
Grade (well/moderately/poorly differentiated) 
Lymphovascular invasion (Y/N) 
 
Figures/Tables 
Table 1 – Demographics / oncological data 
Table 2 – Multivariable model 








Time to death (Overall survival) Date of death 




Tumour behaviour – stage before vs stage after NAC 
Recurrence patterns – local /systemic effect or both. Compare with CRT ? 
Importance of down-staging compared to other prognostic factors 
Implications for staging 
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